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Lateral flow assays (LFAs) are user-friendly diagnostic test devices most commonly 
known from the home pregnancy tests. Since their appearance in the market in 1980’s, 
LFAs have become well-established and products have been developed for various 
applications, but the most commonly sold LFAs still have the same basic features as the 
early products. Compared to other rapid diagnostic test (RDT) platforms, the main 
benefits of LFAs include inexpensive manufacturing costs, relatively fast assay 
development process, and the stand-alone capability of the test to be used without any 
instrumentation.  
 
The analytical membrane that provides the solid support for the bioassay reagents and 
allows the liquids to migrate through the binder lines by capillary force is almost 
exclusively manufactured of nitrocellulose. As the nitrocellulose remains the most 
widely used material, its optical properties, mechanical robustness, and chemical 
stability are not optimal for the RDT development. However, the established status of 
the nitrocellulose membrane in the RDT industry and the continuous product 
development suggests that the material will remain in LFAs for years to come.  
 
Typically, in LFAs, the coloured reporter particles form visible lines on the analytical 
membrane depending on the presence or absence of the analyte of interest. The visible 
lines can be interpreted visually without any instrumentation. However, the visual 
assessment of the assay read-out is prone to subjectivity in interpretation and can be 
affected by poor lighting conditions. Moreover, the visual read-out can only be used to 
generate a qualitative or a semi-quantitative result. 
 
The versatility of the lateral flow technology can be improved by using efficiently 
quantifiable reporter technologies such as fluorescent nanoparticles. However, the 
drawback of pursuing high analytical sensitivity and quantitative results by fluorescent 
reporter is the apparent need for a reader instrument. With fluorescent reporters, the 
optical properties of the assay membranes and sample fluids must be considered in 
order to achieve minimal interference to the detection of the reporters. 
Autofluorescence originating from the assay materials can be avoided by using the 
upconverting nanoparticle (UCNP) detection technology. Nevertheless, the non-
analyte specific background signal can still occur from non-specific binding of the 




The aim of the thesis is to explore the opportunities arising from the use of different 
fluorescent reporter particles to improve the analytical sensitivities of LFAs, and to 
evaluate the feasibility of fluorescent reporter particles as a substitute for common 
visually detectable reporters. Exploiting the increased detectability of the reporter 








Lateraalivirtausmääritykset ovat helppokäyttöisiä diagnostisia testilaitteita, jotka ovat 
tulleet tunnetuksi kotona tehtävistä raskaustesteistä. Tultuaan markkinoille 1980-
luvulla lateraalivirtausmääritykset ovat saavuttaneet vakiintuneen aseman ja tuotteita 
on kehitetty monenlaisiin sovelluksiin. Useimmissa kaupallisissa lateraalivirtaus-
määrityksissä hyödynnetään kuitenkin edelleen samoja perusominaisuuksia kuin 
varhaisimmissa kaupallisissa tuotteissa. Merkittävimpinä etuina lateraalivirtaustesteissä 
muihin pikatestikonsepteihin verrattuna on edulliset valmistuskustannukset, nopea 
määritysten kehitysprosessi sekä mahdollisuus käyttää määrityksiä ilman erillisiä 
laitteita. 
 
Analyyttinen kalvo toimii biologisen määrityksen sitojamolekyylien kiintokantajana ja 
mahdollistaa määrityksen liuosten kulkemisen sitojamolekyyliviivojen läpi. Analyyt-
tinen kalvo valmistetaan yleisimmin nitroselluloosasta, vaikka sen optiset ominai-
suudet, mekaaninen kestävyys ja kemiallinen pysyvyys eivät ole optimaalisia pikatestien 
kehittämistä varten. Nitroselluloosan vakiintuneen aseman pikatestiteollisuudessa ja 
nitroselluloosakalvojen valmistusprosessien kehittymisen perusteella nitroselluloosan 
korvautumista muilla materiaaleilla ei ole odotettavissa lähivuosina.   
 
Tyypillisesti lateraalivirtausmäärityksissä käytettävät värilliset leimapartikkelit muodos-
tavat silmin nähtävät viivat analyyttiselle kalvolle riippuen määritettävän analyytin 
läsnäolosta. Tuloksen tulkintaan ei tällaisessa määrityksessä tarvita erillistä mittalaitetta. 
Määritystuloksen visuaalinen tarkastelu on kuitenkin subjektiivista ja lisäksi huonot 
valaistusolosuhteet voivat aiheuttaa virheellisiä tuloksia. Visuaalisen tuloksen tarkas-
telun puutteena on myös kvantitoitavuuden puute, sillä silmämääräisesti tarkasteltavat 
tulokset voidaan tulkita ainoastaan kvalitatiivisesti tai puolikvantitatiivisesti. 
 
Lateraalivirtausmääritysten käyttökelpoisuutta erilaisiin sovelluksiin voidaan parantaa 
käyttämällä kvantitatiivisia leimateknologioita, kuten fluoresoivia nanopartikkeli-
leimoja. Korkean herkkyyden ja kvantitatiivisten tulosten tavoittelemisessa 
fluoresoivien partikkelien haittapuolena on kuitenkin tarve käyttää erillistä 
mittalaitetta. Fluoresoivia nanopartikkelileimoja käytettäessä on myös huomioitava 
kalvomateriaalin ja näyteliuoksen optiset ominaisuudet mittaustarkkuutta heikentävien 
häiriöiden minimoimiseksi. Näytteestä ja kalvomateriaaleista johtuvaa autofluore-




Autofluoresenssin lisäksi epäspesifistä signaalia määrityksessä aiheuttaa myös 
analyyttiselle kalvolle juuttuneen leimapartikkelit. 
 
Tämän väitöstyön tavoitteena oli tutkia erilaisten fluoresoivien leimapartikkeleiden 
tuomia mahdollisuuksia lateraalivirtausmääritysten analyyttisen herkkyyden paranta-
miseksi sekä arvioida mahdollisuuksia korvata tavallisia visuaalisesti tarkasteltavia 
leimapartikkeleita fluoresoivilla leimapartikkeleilla. Fluoresoivien partikkeleiden hyvän 






During the late 1980s, the rapid test for pregnancy became available for home testing 1-
3. The pregnancy test’s distinctive appearance with a self-contained assay device with 
visual lines appearing on a blank membrane became well-known. The rapid diagnostic 
tests (RDTs) based on such structure are commonly known as lateral flow assays (LFAs). 
Since the introduction of LFA for pregnancy testing, numerous other RDT applications 
have been developed mostly for clinical applications but also for other market segments 
such as food safety4 and environmental diagnostics5 using the lateral flow (LF) platform6.  
The most typical variant of LFAs is the lateral flow immunoassay (LFIA), also known as 
immunochromatographic assay or sol particle immunoassay7. In LFIA, antibodies are 
used to bind the target analyte from the sample fluid and detect a signal output 
generated by the antibody–antigen interaction. Immunoassay, in the original format 
that was first described in 1959, had mostly been restricted to laboratory use due to the 
requirements of precise liquid handling capability and sophisticated instruments.8 
Furthermore, the latex agglutination test  from 19599 can be considered an another 
predecessor of the LFA. 
However, following the home pregnancy test the trend to perform clinical diagnostics 
in point-of-care (POC) conditions has become more apparent. In addition to the 
pregnancy test, the most prominent simple POC assays include amperometric blood 
glucose tests10, colour-indicator urine dipsticks11, and lateral flow assays for human 
immunodeficiency virus (HIV)12. Owing to the simple usability, very low manufacturing 
costs13, and rapid prototyping process14, the LF-platform is the most popular format 
used in rapid immunoassays. The technology has gained wide acceptance in resource-
poor conditions where the possibilities to perform clinical laboratory diagnostics is 
limited due to the lack of facilities, machinery, and trained staff.  
Despite the many advantages of the technology15, the applicability of LFIAs is limited by 
certain shortcomings. Assays requiring high analytical sensitivity or quantitative results 
may not be possible to produce by using the traditional reporter and detection 
technology relying on the visual interpretation of the test line intensity. Most of the 
currently available LFAs are usually capable of qualitative or semi-quantitative analysis 
with visually detectable reporter particles.6 These limitations are logical considering the 
signal detection mechanism of the assay. The result is commonly inspected by the 
formation of visible test lines on the membrane, and the amount of the reporter particles 




reflection. The visual interpretation of the assay read-out does not require any 
instrumentation, but the capability to produce quantitative data can only be achieved 
by using reader instruments.  
This thesis examines the potential of luminescent reporter particles in extending the 
capabilities of lateral flow assays. Special focus is placed on the upconverting phosphor 
nanoparticle (UCNP) technology16 due to its unique feature of excluding all non-
reporter-specific luminescence from the measurement17. The following literary review 
will focus on sandwich immunoassays in LF-platform with optically detectable 
reporters, providing an overview of the current technologies and the emerging 
opportunities with technological improvements.
Review of the literature 
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2 REVIEW OF THE LITERATURE 
2.1 Lateral flow assays 
The concept of point-of-care (POC) testing has been defined in multiple ways, 
depending on the focus of the literature in question. Despite the differences, the 
consensus is as follows: “patient specimens assayed at or near the patient with the 
assumption that test results will be available instantly or in a very short timeframe to 
assist caregivers with immediate diagnosis and/or clinical intervention”.18 
The conditions where POC tests are used are very diverse. Simple and rapid tests are 
useful in very resource-limited conditions as well as in well-equipped primary care 
centres and hospital wards19. In modern healthcare settings in industrialized countries, 
the point-of-care tests are used by the primary care clinicians to support making the 
diagnosis20. The POC tests are valued for their promptly available results in both 
sophisticated medical care settings and developing countries where they are even more 
significant. In conditions where centralized laboratory diagnostics is not available to the 
public due to the lack of logistics, facilities and trained laboratory personnel, the rapid 
diagnostics tests (RDTs) have been successful in providing information of the causative 
agents of relevant infectious diseases21-23.  
Because of their low manufacturing costs, relatively quick assay development time, and 
user-friendly operating procedure, lateral flow assays (LFAs) have become a widely used 
format of affordable RDTs6. The World Health Organization’s (WHO) list of 
prequalified diagnostic tests (updated 17 March 2017), which has been maintained since 
2010, contains altogether 67 products, of which 31 are lateral flow assays with either 
antibodies or antigens used as binder molecules. The prequalification status indicates 
that the test performance matches the criteria defined by WHO.24  
Despite being an established platform technology for the RDTs, most of the LFAs still 
rely on visual examination of the formed signals. In many cases, especially with 
occasionally used over-the-counter tests, a dedicated LFA reader device is not desirable 
by the consumer. This limits the use of LFAs to assays which do not require high 
analytical sensitivity or quantitative results. The selection of potential LFA applications 
can be broadened by implementing a reader device and a compatible reporter 
technology that upgrades the assays with higher analytical sensitivity and quantitative 
or semi-quantitative results. 
Review of the literature 
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LFIA technology as a research subject has become more popular after the turn of the 
millennium. Articles mentioning lateral flow immunoassay or immunochromatography 
were searched for on PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) using search 
terms “immunochromatograph*” and ‘”lateral flow” assay’. A total of 2745 publications 
mentioned immunochromatography in 1984–2015 and 1211 mentioned lateral flow assay 
in 1978–2016. A significant incline in the annual number of articles has taken place after 
the year 2000 (figure 1). Rarely used terms “sol particle immunoassay” and “sol particle 
assay” yielded only 21 distinct publications.  
Figure 1. Numbers of research publications mentioning sol particle immunoassay, 
immunochromatography or lateral flow immunoassay from 1964 to 2016. 
A database search for patent applications using Espacenet patent search 
(https://fi.espacenet.com/) with search terms ‘“lateral flow” assay’ yielded a total of 541 
hits and “immunochromatograph*” yielded 1382 hits. The annual numbers of patent 
applications follow the growing trend of increasing number of research publications 
(figure 2). First patent application mentioning immunochromatography was filed in 
198225. In 2007, a major increase in filed patent applications coincided with the 
expiration a of patent entitled “Solid phase assay with visual readout”1. Another 
fundamental patent covering the use of monoclonal antibodies in 
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Figure 2. Annual numbers of patent applications mentioning immunochromatography 
or lateral flow assay from 1982 to 2016.  
2.1.1 From discovery of capillary action to biochemical assays 
According to J.C. Poggendorff, the capillary action was first described by Leonardo Da 
Vinci27. However, the understanding of the phenomenon started to emerge along the 
scientific revolution with the paradigm shift from Aristotelian mechanics to classical 
mechanics. In 1661, Robert Hooke presented a finding stating that the narrower the 
tube, the higher water rise in it28. Hooke was guided and employed by Robert Boyle who 
believed capillary action had been discovered by “some inquisitive Frenchmen”29. Boyle 
later became famous for the Boyle’s law describing the relation of gas pressure and 
volume. The fundamental mechanics in capillary action are based on two phenomena: 
cohesion and adhesion30. Cohesion in this context refers to the intramolecular non-
covalent forces attracting molecules towards each other to form a droplet. Adhesion in 
the capillary action means the non-covalent attractive forces between the liquid droplet 
and an external surface. The mechanisms of intramolecular interactions were practically 
unknown at the time when the significance of cohesion and adhesion were described in 
capillary action. Especially in water, the hydrogen bonding by electrostatic attraction of 
the water molecule dipoles contributes significantly to the cohesive forces.31-33 
Quantitative explanation of capillary action was published by Carl Friedrich Gauss in 
1830 based on the research of Thomas Young, who developed the qualitative theory of 
surface tension, and Pierre-Simon Laplace, who presented the mathematical description 
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the quantification of the capillary force as it can be used to calculate the capillary 
pressure across the interface of liquid and air.34 
∆  (1) 
In the equation Δp is the pressure difference across the interface, γ is the surface tension 
as R1 and R2 are the radii of curvature. In 1959, Yalow and Berson presented the first 
immunoassay. The target analyte insulin was quantified by measuring the presence of 
I131-labeled insulin which competed of binding with endogenous insulin.8 The 
exploitation of the capillary action in immunoassays has revolutionized the rapid 
diagnostic testing by providing a concept of mass-producible, affordable and robust test 
kits. The first application of lateral flow immunoassay (LFIA) technology that gained 
popularity, and still remains the most popular over-the-counter test kit for human 
chorionic gonadotropin (hCG), was used for testing for pregnancy. Following the 
pregnancy home tests, various other test kits utilizing LFIA have established their 
position on the market. Especially the LFIAs for HIV and malaria have been recognized 
to have a major impact on global healthcare22, 35-38. 
2.1.2 Lateral flow market segments 
The largest segment of the LFA market is currently in clinical diagnostics with the 
pregnancy tests still being the source of most revenue covering 89 % of the total revenue 
in 2010. Within the clinical diagnostics segment, the test kits for infectious diseases are 
the second and the test kits for cardiac markers the third most sold POC applications 
after pregnancy tests. The second largest market segment is the veterinary health 
diagnostics with approximately 9 % of the revenue. The rest of the market segments 
covering a total of 3 % of the total market revenue consists of food and beverage 
manufacturing, pharmacological quality control, environment diagnostics, and water 
utilities.39, 40  
Various potential application segments for LFAs are currently emerging. For example, 
WHO has identified that counterfeit medicines are a serious issue especially in the 
developing countries.41 Testing for such counterfeits, simple-to-use rapid tests could be 
provided to ensure the originality of the drug. For personal medicine, a rapid test for 
monitoring the levels of anti-TNF-α monoclonal antibodies used in treating 
autoimmune disease symptoms has been reported.42 In veterinary health diagnostics, 
the most common LFAs include cow-side milk progesterone tests43, feline leukemia 
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virus tests44, and rapid tests for canine parvovirus45. In agriculture, rapid diagnostics for 
detecting plant pathogens are being developed.46  
Furthermore, interest in the use of LFAs in food-safety testing is also growing47, 48 as 
multiple tests are commercially available for food processing contaminations and 
international regulations for the testing of contaminations have been implemented49. 
For example, a rapid test can be used for detecting ochratoxin in wine50 or aflatoxin M1 
in milk51. In food industry, certain specific cross-contaminations, such as peanut and 
hazelnut, can be tested with a simple LFA52. The use of rapid diagnostic assays for 
chemical and biowarfare agents is also a significant application area of LFAs53-55, 
although it is intended for a more specific professional use rather than a large consumer 
business. 
The total estimated value of the global POC market was $19.3 billion in 2016, with the 
U.S. market covering $9.7 billion and Europe $4.8 billion56. 
2.1.3 Principle structure and function 
Most commonly available LFA test kits have an assay cassette (figure 3) that contains the 
assay strip and, in some cases, a desiccant tablet. The plastic cassette allows the liquid to 
be applied to the assay strips without the need to dip the strip into the liquid. In addition 
to providing mechanical durability, the cassette also contains the biological fluids tightly 
inside and reduces the user’s exposure to potentially hazardous fluids. In all the assay strip 
membranes, the structural strength needs to be sufficient to withstand the mechanical 
stress of the reel-to-reel assembly process. Especially the sample pad and conjugate release 
pad must retain the tensile strength even when wet from the blocking solutions57. 
Structure and function of a typical lateral flow assay strip 
A common feature in all lateral flow assays is that the capillary action drives the liquid 
movement. The strip typically contains two printed capture zones, a test line and a 
control line, where the immunoassay reporters form detectable lines depending of the 
presence or absence of the analyte.3 Although the exact details on the material 
compositions and manufacturing processes are proprietary trade secrets of the 
companies, the basic principles of the LFA composition are in the public domain. The 
binder lines are typically dispensed using a contact- or non-contact dispensers. The 
contact dispensing units such as BioDot Frontline HRTM or Imagene Technology 
IsoFlow™ Low Contact Pressure nozzle typically have a syringe pump-actuated liquid 
dispensing mechanism and nozzle capillaries dragged on the analytical membrane. 
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Non-contact dispensers spray the binder solutions through a solenoid-actuated nozzle 
like in BioDot BioJet HRTM dispenser or piezo-actuated nozzles like in Scienion 
sciFLEXARRAYER dispensers. Multiple strategies for controlling the liquid flow and 
introducing sequential flow of multiple reagents by different liquid barriers, on/off-
switches and membrane configurations have been reported58, 59. Currently such gating 
functions are rare in commercially available LFAs.  
Some variations of the standard LFA-structure have been published with different cross-
flow configurations60. For example, Dual Path Platform (DPP) by Chembio Diagnostic 
Systems Inc.  (Medford, NY, USA) has successfully entered the market and has an 
established status in RDTs for infectious diseases24.  
 
Figure 3. A typical assay cassette used in LFAs. A) A top view of a cassette with separate 
inlets for sample fluid and washing buffer. B) A view of the cassette with the top cover 
part sliced. C) The membrane assembly strip contained inside the cassette comprising 
sample pad (I), conjugate pad (II), nitrocellulose membrane (III), printed test and 
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Competitive and non-competitive immunoassays 
Both, competitive- and non-competitive formats of immunoassays have been 
successfully used in the LF-platform. Competitive LF immunoassays have been 
developed for low molecular weight analytes such as vitamin B1261, progesterone62, 
cortisol63, testosterone64  food toxins50, 65 and multiple drugs of abuse66, 67 
In the two formats of competitive immunoassays the analyte of interest either competes 
of (a) solid-phase binding sites with a reported-conjugated analyte analogue or (b) 
blocks the binding sites of reporter-conjugated antibodies.6 In the latter format the 
binding of antibody-conjugated reporters to the immobilized analyte analogue is 
prevented by the abundance of the measured analyte. Thus, the abundance of the analyte 
in the sample is observed by the decrease of the reporter-specific signal.6, 57 Non-
competitive immunoassays (also referred to as sandwich immunoassays or direct 
immunoassays) are typically preferred when the analyte has multiple immunogenic sites 
and a sufficient size to react with two binding antibodies.39 Generally, non-competitive 
immunoassays allow wider dynamic range than competitive immunoassays due to the 
reason that the concentration of competing analyte analogue must be in a range where 
analyte-induced signal inhibition is measurable. However, competitive immunoassays 
can be used for analytes too small for non-competitive immunoassays.68 
Binder molecules 
The binder molecules commonly used in LFAs include monoclonal or polyclonal 
antibodies, and recombinant or native antigens. Most commonly, the antibodies are 
used as the analyte-binding molecules in LFIAs. In both assay formats, competitive and 
non-competitive immunoassay, the use of antibodies is required. The exception is the 
assays detecting antibodies against specific pathogenic molecules which use antigens as 
the binding reagents. For the test line printed on to the nitrocellulose, monoclonal 
antibodies of Immunoglobulin G-class (IgG) are most commonly directly adsorbed on 
to the nitrocellulose matrix. As the adsorption of the protein to the nitrocellulose matrix 
may not be efficient enough or the protein functionality may be compromised in the 
adsorption  process, there are strategies to modify the antibodies or use generic tag-
binding proteins such as streptavidin69 to achieve better compatibility with the 
adsorption on to the nitrocellulose.70  




Analytical membrane is the porous matrix through which the liquid passes onto the 
absorbent pad. Currently, the analytical membranes are almost exclusively made of 
nitrocellulose (figure 4). However, alternative materials have been reported. Instead of 
an actual membrane, the capillary flow can be achieved by using micropillar surface 
manufactured of hot-embossed cyclo-olefin polymers71. Such technology was patented 
by Åmic AB, Uppsala, Sweden72, 73. Currently, the micropillar technology has not been 
adopted in many products with the exception of the Meritas POC concept by Trinity 
Biotech, which includes a rapid test for cardiac troponin I74. 
 
Figure 4. Chemical composition of a nitrocellulose polymer subunit. 
Nitrocellulose membranes with different liquid flow rates (also referred to as “wicking 
rate” or “capillary rise time”) are manufactured commercially (Table 1). The flow rate is 
dependent of the pore size of the membrane and the surfactants used in the 
manufacturing. Therefore, the flow rate is considered a more comparable parameter in 
LFA-development process than the actual pore size. The flow rate is defined as time in 
seconds that it takes for the fluid front to move 40 mm.57 The flow rate, however, is not 
constant throughout the length of the strip. The flow becomes slower as the fluid 
proceeds through the porous matrix75. During the wetting of the membrane, the liquid 
flow can be approximated with the simplified Washburn equation (2)76, 77. 
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In the equation, L is the length of the fluid column in the porous matrix, γ is the fluid 
surface tension, dp is the pore diameter, θ is the contact angle of the liquid on the 
capillary material, μ is the dynamic fluid viscosity, and t is the elapsed time. Steepness 
of the liquid contact angle is dependent on the hydrophobicity of the matrix surface as 
a more hydrophobic surface tends to minimize the contact area between the fluid and 
the surface. Hydrophobicity is defined by IUPAC as “the association of non-polar 
groups or molecules in an aqueous environment which arises from the tendency of 
water to exclude non-polar molecules”78 and in this context refers to the lack of 
attractive forces between polar and non-polar substances. 
After full wetting, the liquid flow can be approximated with Darcy’s law (3) for flow in 
porous media.79, 80 
Q=- ∆  (3) 
In the equation, Q is the volumetric flow rate, κ is the permeability of the matrix, wh is 
the cross-sectional matrix area, μ is the dynamic fluid viscosity and ΔP is the pressure 
drop over the length of the whole matrix. 
In both equations, simplifying assumptions have been made to allow mathematical 
modelling of a complex system. Neither of the presented equations used to approximate 
the flow characteristics in porous media take into account the ambiguous pore structure 
and possible structural changes of the porous matrix due to wetting. The Washburn 
equation (2) assumes that the capillary matrix consists of a multitude of uniform 
capillaries having a circular cross-section, the effect of gravity or air resistance is 
negligible and the pressure difference over the interface of liquid and air follows the 
Young-Laplace equation (1).77 The equation (3) derived from Darcy’s law assumes that 
the liquid flow is laminar (i.e. no turbulence occurs in the flow), the liquid is 
incompressible, the permeability and the cross-sectional area of the matrix are constant 
throughout the system. The Reynold’s number describing the turbulence properties of 
the water flow is approximately 10-3 in nitrocellulose membranes. Thus, the flow is 
considered laminar and the approximation is applicable.75 
The manufacturers generally recommend smaller pore size and slow flow rate 
membranes for LFAs requiring high analytical sensitivity, and larger pore size 
membranes for shorter assay time and less-demanding sensitivity requirements. The 
trade-off situation between assay sensitivity and liquid flow results in a compromise of 
the assay time and analytical sensitivity81.  
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Table 1. Commercially available analytical membranes intended for use in LFAs. 
 
Nitrocellulose membrane is typically manufactured by casting the nitrocellulose in a 
solution of organic solvents on to a polyester or polyethylene terephtalate backing in to 
100 m master rolls82, 83. The porous structure is formed as the solvent evaporates from 
the cast nitrocellulose sheet84. As the thickness of nitrocellulose membranes typically 
used in LFAs is approximately 100 to 150 μm82 and the evaporation occurs only from 
the air side, the porosity of the membrane is smaller at the side of the backing (figure 5).     
 
Figure 5. Scanning electron micrograph of an AE 100 unbacked nitrocellulose 
membrane (GE Healthcare Life Sciences). A) air (top) side and B) belt (bottom) side. A 
significant asymmetry can be observed between the two sides due to the evaporation of 








Pall Corporation Sartorius 
Immunopore RP HI-Flow™ Plus HF75 CNPH-N SS40 70 LFNC-C 15 μm Vivid™ 90 UniSart® CN95 
FF80HP HI-Flow™ Plus HF90 CNPH-N SS40 90 LFNC-C 12 μm Vivid™ 170 UniSart® CN110 
FF120HP HI-Flow™ Plus HF180 CNPH-N SS60 150 LFNC-C 10 μm  UniSart® CN140 
FF170HP HI-Flow™ Plus HF135 CNPH-N SS60 200 LFNC-C 8 μm  UniSart® CN150 
 HI-Flow™ Plus HF120 CNPF SN12 10 μm LFNC-H 15 μm    
  CNPF SN12 8 μm LFNC-H 12 μm    
  CNPF SN12 5 μm LFNC-F 90   
  CNPF SS12 15 μm LFNC-F 130   
  CNPF SS12 12 μm LFNC-F 150   
  CNPF SS12 10 μm LFNC-F 170   
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Considering the anisotropy of the porous nitrocellulose matrix with the smaller pore 
size on the backing side of the membrane and the liquid flow equations (1–3), the liquid 
flow is expected to be slower at the backing side of the nitrocellulose membrane. 
Absorbent pad 
Absorbent pad, also known as wicking pad, serves as the sink to where the liquid passes 
through the analytical membrane and is absorbed to maintain the flow capacity by 
capillary action. The absorbent pad is usually manufactured of cellulose (table 2), and 
its size is estimated so that it is able to absorb all the liquid applied to the assay strip or 
a limiting capacity can be used to stop the liquid flow at a desired time.57 
Conjugate release pad 
Conjugate release pad contains the reporter particles that are released by the liquid flow 
to interact with the analyte and to bind to the test or control line. The pad is usually 
manufactured from glass fibre or polyester (table 2) and treated with impregnation 
solution typically containing polymers, surfactants, and proteins to achieve effective 
conjugate release properties and rapid wettability. The reporter conjugate is typically 
deposited to the release pad by a mechanical liquid dispenser or by immersion57, 85.  
Sample pad 
The sample pad is the first material on the LF strip assembly to contact the sample liquid. 
The main function of the membrane is to absorb the sample fluids and release the fluids 
to the analytical membrane via conjugate release pad. The sample pad is commonly 
manufactured of glass fibre (table 2), but also cellulose or rayon have been used86. The 
sample pad can also contain dried reagents such as buffering components, salt or inert 
proteins to adjust the reaction conditions, such as pH and salinity, without adding 
separate buffer solutions.57 
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The components of LFA are assembled on the backing laminate manufactured of 
polyester, polystyrene or polyvinylchloride (PVC), or mixtures of the previous. The 
laminate is covered with pressure-sensitive adhesive to enable the binding of the assay 
components. Commonly, a thicker backing laminate is recommended for assays done 
in the dipstick format, as the strips used inside a plastic cassette are usually 
manufactured with thinner laminates to reduce the wearing of the strip cutter blades. 
The adhesive used in the backing laminate must be soft enough to provide sufficient 
adhesion, but hard enough to avoid the migration of the adhesive into the assay 
membranes. Adhesives typically used in the backing laminate, such as KN-2211 
(Kenosha C.V., Netherlands), do not adhere instantly when the membranes are 
attached, but form a strong bonding within 24 hours.87 
Auxiliary components 
A plastic case is often included to provide a sample inlet serving as a reservoir for the 
sample fluid. The rigid structure of the plastic case also provides mechanical stability for 
the assay strip assembly and often contains desiccant that absorbs moisture to extend 
the product’s shelf-life82. The plastic cassette must hold the assay firmly in a correct 
position without choking the liquid flow by applying pressure to the membranes.  
Especially in the LFAs used in the dipstick format, the membranes are typically covered 
by a transparent adhesive film printed with assay identification markings and sample 
application point indicators. The film provides structural integrity to the strip, prevents 
liquid evaporation, and protects the analytical membrane from damage. 
2.1.4 Reporter particles 
Reporter bioconjugation  
The inherent protein-binding feature of the colloidal offers a convenient way to produce 
a reporter bioconjugate. The optimal amount of protein used in the conjugation can be 
determined by the amount of protein that prevents the visible aggregation of gold 
particles.88 For reporter particles with carboxyl-modified surface a popular method for 
covalent linking of the biomolecule and the reporter is done by carbodiimide linkage 
using N-(3-Dimethylaminopropyl)-Nʹ-ethylcarbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide (NHS) as a stabilizing agent.89 In LFAs, the covalent protein 
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conjugation with activated latex is a common method that also enables controlled 
orientation of the antibody in the conjugation.39    
Visually detectable reporters 
Gold particles, also known as colloidal gold, are the most commonly used reporter 
technology. The inherent physical characteristics of gold also enables the measuring of 
the colloidal gold in LFAs with surface-enhanced Raman spectroscopy (SERS)90 or 
localized surface plasmon resonance (LSPR)91. A reporter particle specially optimized 
for SERS detection and consisting of gold core in a silver shell has been reported to yield 
analytical sensitivity higher than that provided by chemiluminescent detection 
technology92. The typical analytical sensitivities achieved using visual detection of 
reporters in LFAs ranges from to 3 pM to 10 μM.93 
Various methods for improving the assay sensitivity with visually detectable reporters 
have been described. The detectability of colloidal gold can be improved up to 400-fold 
by using an electrokinetic pre-concentration method94 or up to 500-fold by using a silver 
enhancement method to increase the light absorptivity of colloidal gold95, 96.  
Visually detectable reporters also include the enzymatic reactions used to generate a 
visible substance at the test line where the immunocomplex formation occurs. The 
presence of analyte can be indicated by tracer antibodies having the colour-reaction 
catalysing enzymes conjugated with antibodies or alternatively enzymes produced as 
fusion proteins. Such technology has been described most commonly using horse-
radish peroxidase (HRP) as the catalyst enzyme.60, 97, 98 Enzyme-coupled tracer 
antibodies are not only used as visually detectable reporters, but also used in 
electrochemical detection in LFAs64, 99. 
Carbon nanoparticles have been reported as a reporter technology well suitable for rapid 
diagnostic assays100, 101. The main benefits of the technology over the colloidal gold are 
better contrast on the white nitrocellulose membrane and low-cost manufacturing 
process.102 The carbon nanoparticles have been reported to yield better analytical 
sensitivities compared to colloidal gold or latex in a variety of LFIAs93, 103. An analytical 
sensitivity of 31 pg/mL in a rapid LFA for mouse and rat urinary proteins demonstrates 
that sensitivities comparable to fluorescent reporters can be achieved using carbon 
nanoparticles.104  In addition to carbon nanoparticles used as visually detectable 
reporters there are also fluorescent carbon nanoparticles105 that have been used for cell 
imaging.106 Currently, there are no publications of the fluorescent carbon nanoparticles 
being used in LFAs. 




In his article describing the conversion of incident ultraviolet light to an emission of 
blue light by fluorite, Sir George Gabriel Stokes named the phenomenon fluorescence107. 
The shift of wavelength from shorter to longer in a fluorescence process, named after 
Sir Stokes as the Stokes’ shift, is a fundamental feature of fluorescent molecules used as 
reporters in biochemical assays 108, 109. Generally, fluorescence refers to a process leading 
to the emission of light from a material that has absorbed electromagnetic radiation.78 
This differs from the normal reflection of light by the occurrence of intramolecular 
energy transfer processes that convert the radiation energy absorbed by a material to an 
emission of photons at different wavelengths characteristic to the energy transitions 
within the material.  
Europium(III) nanoparticles were described as an LFA reporter for the first time in 2007 
in an assay for blood eosinophils and neutrophils110. A subsequent publication on 
Eu(III) chelate loaded silica shells described a method for imaging the LFAs with Eu(III) 
reporters by using a digital camera.111 Near-infrared (NIR) dyes have been reported to 
be feasible for LFA-applications due to the low-degree of autofluorescence originating 
from the assay materials and sample fluids at the near-infrared range.112  
Furthermore, it is possible to exploit the quenching capability of fluorescent reporters 
to generate analyte-specific assay response. In a recent article, quantum dot reporters 
were conjugated with analyte-specific antibodies and immobilized to the test line of the 
LFA strip. Graphene oxide was used to reveal the antigen binding to the quantum dot 
particle, as graphene oxide was only able to quench the fluorescence from quantum dots 
not masked by the bound antigen.113 Such a method could potentially be advantageous 
for multiplex assays, as there would be no need to dry multiple different reporter 
bioconjugates on the conjugate pad. 
Non-optical reporters 
The amount of reporter particles retained on the test line can be measured also with a 
magnetic field. The magnetic field induces a measurable modulation in the radio 
frequency (RF) signal in close proximity to the test line.114 The magnetic detection has 
shown potential for the production of high detection sensitivity. With 
superparamagnetic particles, an LFA for cTnI has been reported with an analytical 
sensitivity of 0.01 ng mL-1.115  
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Different electrochemical detection technologies have also been reported with LFAs. 
The change of electric conductivity or the generated current in the presence of certain 
reporters can be measured with simple electrodes attached to the membrane.116 The 
electronic current generated by a redox reaction catalysed by HRP was used as a signal-
generating part of the reporter bioconjugate.64 An LFIA for cardiac troponin I (cTnI) 
using an electrochemical reporter system with β-galactosidase-conjugated (IgG)99 has 
been described with an analytical sensitivity of 0.1 pg mL-1, and another LFIA for the 
measurement of cortisol from saliva with glucose oxidase-conjugated reporters has been 
reported with a dynamic range of 1–10  ng/mL.117 
2.1.5 The advantages and limitations of the LF-platform 
Liquid movement by capillary action 
A cornerstone of the popularity of the lateral flow platform is the simple and robust 
mechanism of agitating the liquid flow over the bioreactive surface. The surface is 
manufactured on a membrane with capillary flow wicking properties. Typically the 
surface is manufactured from nitrocellulose, but alternative technologies, such as 
micropillars embossed on cyclo-olefin polymers (COP), have been envisioned to 
overcome the limitations of the nitrocellulose71, 118. Other, very affordable and 
mechanically robust materials, for instance, plain cellulose paper119 and even cotton 
threads, have been investigated120. It seems that the liquid flow by capillary action 
enables the tests to be used without any instrumentation, but certain drawbacks, such 
as limited immunoassay kinetics, originate from the fixed flow rate determined by the 
analytical membrane. 
Controlling the protein binding 
Typically, the antibodies on the test line are printed without any attempts to produce 
covalent binding to the surface. The proteins are allowed to dry completely and bind on 
the membrane by the non-covalent interactions of the protein and nitrocellulose. 
Therefore, a certain degree of the protein-binding feature in the nitrocellulose is 
desirable. However, as the reporter particles have typically been conjugated with an 
antibody or an antigen, the same protein-binding feature tends to bind the 
bioconjugated reporter particles. 
The binding of proteins to the test line relies on the affinity of the protein and the 
nitrocellulose membrane. The non-covalent affinity has been reported to be 
thermodynamically driven75, 121 but it is still disputed, whether the affinity originates 
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from dipole–dipole attractions or hydrophobic interactions.75 After dispensing, the 
proteins are typically dried in 35–40 ° C for 1–2 hours.57, 122, 123 In the in-line production 
system, the nitrocellulose with the dispended protein travels through a dry tower as, for 
example, in the RR120 Web Handling Platform (BioDot Inc, Irvine, CA, USA). 
Multiplexing 
Having assays for multiple analytes can be done by having multiple assay strips inside a 
single cassette. In this kind of a cassette, the reaction conditions, such as binder molecule 
density, can be optimized individually and analytical membranes of different wicking 
rates can be selected. Producing multiple test lines for each analyte on the same strips is 
very common in commercially produced LFAs. For example, the SD Bioline HIV‐1/2 
3.0 (Standard Diagnostics) rapid test for anti-HIV antibodies has two test lines: one for 
HIV-1 and another for HIV-2. The drawback of having multiple immunoreactions on 
the same strip is that the different reporter particle bioconjugates may not work as 
optimally as in single-plex assays. 
Multiplex immunoassays on the LF-platform can also be achieved by printing an array 
of binder molecules on the analytical membrane in multiple spots. Such lateral flow 
microarray immunoassays (LMIAs) have been described for use in biomarker 
screening124 and amplicon detection NALFIAs102. 
In late 2016, Sartorius presented analytical membranes for multiplex LFAs by printing 
hydrophobic barriers into the nitrocellulose membranes. The Unisart StructSure® 
membranes (Sartorius AG, Germany) are custom produced according to the 
specifications of the assay design. Similar strategies have been reported by printing 
hydrophobic barriers with polydimethylsiloxane (PDMS)125 or molten wax126. 
Assay kinetics 
The time available for the binder molecules to interact with the analyte is practically 
limited by the time in which the analytes pass the test line. Furthermore, the time that it 
takes to bind the analyte with the reporter particle is another variable that affects the 
degree of immunocomplex binding obtained in the sandwich immunoassay.127  As the 
width of the typical test line is approximately 1 mm, the liquid front passes the reactive 
surface area in 2–5 seconds depending on the flow rate of the nitrocellulose.  A method 
for increasing the reaction time of the reporter particles and the binder surface has been 
described with wax micropillars printed on nitrocellulose128. 




In the typical format of LFIAs, the sample fluid is applied to the sample inlet of the 
cassette and allowed to absorb. After the sample application, a wash buffer is added in 
some cases to rinse the membrane of non-bound reporters and residues of the sample 
fluid. In such a procedure, the sample fluids first come into contact with the dried 
reporter particles on the conjugate pad and the immunoreaction starts with the binding 
of the analyte by the reporter particles and is followed by the binding of the formed 
analyte–reporter complexes by the binder molecules immobilized on the test line. 
The major drawbacks of this immunoassay format include the lack of an effective 
washing step, which limits the use of anti-human antibodies for the detection of 
humoral responses for infections. In addition, the non-related antibodies contained in 
the sample fluid bind to the reporter particle and the disease-related antibodies cannot 
be effectively detected. 
The typical LFIA-format is also susceptible to the high-dose effect that relates to the 
saturation of immunoassay binding sites, also known as “hook” or prozone effect, in 
which a high concentration of an analyte partially prevents the formation of the 
immunocomplex. This is problematic for assays with a wide concentration range, such 
as hCG or malaria HRP-2. The hook-effect may lead to misinterpretation of the test 
result if this possibility is not considered.129-131 
2.2 Fluorescent reporter particles  
2.2.1 Common characteristics 
All fluorescent reporters have the common feature of having the excitation and emission 
light occurring at different wavelengths. Fluorescence in naturally occurring 
compounds always transform the excitation light into emitted light with a longer 
wavelength. This shift of wavelength from shorter to longer is known as Stokes’ shift.107 
For the sake of simplicity, the common term of fluorescence is used in this context 
although the upconversion photoluminescence in the UCNP technology is not 
commonly referred to as fluorescence due to the anti-Stokes’ shift of the excitation 
photons to emitted photons. Still, according to the definition of fluorescence by 
IUPAC78, upconversion photoluminescence is fluorescence. 
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Exclusion of non-reporter-specific fluorescence 
In the fluorescence measurement, the excitation light must be excluded from reaching 
the emission light sensor by using optical filters that block the non-reporter-specific 
light.132 This is known as spectral resolution. In an optimal situation, the emission band 
of the reporter occurs far from the excitation light wavelength that allows the optical 
filters to block the excitation light efficiently while the emission light is transmitted 
without significant loss. Moreover, some lanthanide-ions have a feature of sustaining 
the emission for up to 1 ms. Reporters with such compounds can be measured by using 
a pulsed excitation light and measuring the emitted light after a delay time of 50–500 μs. 
The method is known as time-resolved measurement133, 134 and it is typically used with 
optical filters that enable spectral resolution.135 
Quantum yield 
According to IUPAC, the term quantum yield is defined as the number of defined events 
occurring per photon absorbed by the system.78 In the context of fluorescence, the term 
more specifically refers to the ratio of emitted photons and incident photons. Thus, the 
quantum yield is a parameter of the reporter molecule and it significantly contributes to 
the detectability of the reporter. Particles with high quantum yield require less excitation 
energy to emit photons. For upconverting nanoparticles, the quantum yield has been 
reported to be dependent on the particle size. Micron-sized bulk particles have been 
reported with a quantum yield of 3 %, whereas particles with 100-nm diameter have a 
quantum yield of 0.3 %.136 Compared to a commonly used fluorescence reporter 
molecule fluorescein that has a quantum yield of 85 %137, the quantum yield of the 
UNCPs is relatively low. However, several strategies, including the synthesis of core-
shell particles, for increasing the quantum yield are under intensive research.138 A 
maximum quantum yield of 31 %139 has been reported for Eu(III)-nanoparticles and a 
maximum quantum yield of 73 % for quantum dots 140.  
Photostability 
Organic fluorophores, such as eosin, fluorescein and cyanine dyes, are sensitive to light 
and may permanently lose the fluorescence activity in an irreversible process called 
photobleaching.141-143 The photostability of the reporter must be considered in the LFA 
development to avoid photobleaching of the reporters.144 Even if the reporters remain 
functional in proper storage conditions, the excitation light in the measurement may 
induce photobleaching. The excitation-induced photobleaching demonstrated with 
Eu(III)-nanoparticles was rapid enough to have a practical effect on the immunoassay, 
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and thus remeasurements of the assays may be prone to decreased fluorescence 
activity.145  
In addition to photobleaching, the environment-dependent intermittency of the 
fluorescence known as blinking can occur with organic fluorophores but also with 
quantum dots.146, 147 The strategies for improving the stability of organic fluorophores 
include implementing oxygen depletion, stabilizing additives, and self-healing 
fluorophores.148 The UCNP reporters have exceptional photostability characteristics 
since they do not bleach145 or blink149. However, the YF4-lattice commonly used in 
UCNPs has been reported to dissolve in aqueous solutions with low fluoride content.150 
2.2.2 Quantitative lateral flow assays 
Quantitative, semi-quantitative or qualitative results 
Although LFAs were originally intended for rapid qualitative testing using visual 
interpretation of the formed colour on the test and control lines, the need for 
quantitative results (figure 6A) and the trend towards LFA readers151 has led to a 
growing number of attempts to produce quantitative or semi-quantitative LFAs.57  
The semi-quantitative assays refer to assays that produce more informative results than 
just a positive or negative readout. In a typical semi-quantitative analysis, the analyte 
concentration is reported as “negative”, “low positive” or “high positive” (figure 6B). 
Such information can be useful, for example, in CRP testing where the high positive 
result can be interpreted as an acute bacterial inflammation and low-positive result may 
occur from various other conditions152. The semi-quantitative results are typically not 
comparable with assays done with other methods. In a quantitative assay, the results are 
reported numerically (figure 6A) and they should be universally comparable with 
reference assays with different methodologies. 
In LFAs, semi-quantitative results can be produced by separate test lines indicating high 
and low levels of the analyte. For example, the FebriDX assay (Rapid Pathogen 
Screening Inc. Sarasota, FL, USA) for MxA and CRP uses this approach with a semi-
quantitative  CRP measurement combined with a qualitative (figure 6C) MxA-
measurement.152 Another common strategy is to convert numerical result acquired with 
a reader device into a semi-quantitative result by calibrating the numerical readouts 
with reference values of relevant analyte concentrations50.  




Figure 6. A schematic illustration of A) quantitative, B) semi-quantitative and C) 
qualitative result interpretations. The numerical output of the assay result can be 
interpreted according to the need of quantification and the precision of the assay results. 
As several quantitative LFAs with reflectance-based detection of visually detectable 
reporters have been developed153, 154, there is a growing trend to develop quantitative 
LFAs using fluorescent reporters110, 155-159. The benefit of fluorescent reporters over 
visually detectable reporters is a better discrimination of reporter-specific signal from 
the non-reporter-specific background signal. Whereas fluorescent reporter signal is 










































Review of the literature 
37 
 
reflectance-based measurement cannot exclude non-reporter-specific background 
signals by spectral resolutions because the image artefacts originating from dust-
speckles, scratches or uneven lighting conditions are not limited at any specific 
wavelength range. In addition, higher analytical sensitivities have been reported with 
fluorescent reporters when compared to visually detectable reporters93, 123, 160 
The need for quantitative LFAs  
In clinical diagnostics, the need for quantification is evident in analytes that are 
constantly present in variable concentrations and in situations where the clinical 
condition is related to abnormal biomarker levels. A potential use for a quantitative LFA 
could be in the testing of hormones62, 63, 161, 162, inflammation markers152, 163-166 or 
monitoring biomarkers of non-communicable diseases in resource-limited settings167. 
In the agriculture industry, the ability to quantify the plant pathogens in order to 
optimize the usage of plant protection products would be extremely valuable.46 For 
environmental diagnostics, the need for quantitative results is less obvious. For example, 
a quantitative LFA for detecting microcystins in water can detect the analyte at 
concentrations far below the limit recommended by the WHO for drinking water168.  
However, as the result is eventually considered as ‘acceptable’ or ‘not acceptable’ based 
on the maximum acceptable level of the analyte, the benefit of quantitative result would 
be useful in scenarios with variable acceptable threshold limits. 
2.2.3 Calibration 
To achieve quantitative results, it is necessary to have a calibration method that 
translates the output of the reader device sensor into a comprehensible readout. For this 
purpose, a calibration procedure can be used to generate a regression model of the 
dependency of the numerical output of the test device and the corresponding, measured 
amount of analyte.  
Optical reference standards can be used to calibrate the reader devices in order to 
achieve uniform performances among the reader devices. Lot-specific calibrations of the 
assays must be done to compensate for the differences occurring in the manufacturing 
process. Commonly, the calibration is done by measuring a set of assay lot-specific 
calibrator samples with the reader device and generating the calibration curve based on 
the measured results. The Sofia Analyzer for LFAs with fluorescent reporters (Quidel 
Corp. CA, US) is shipped with an analyzer calibration cassette which is used to re-
calibrate the reader device monthly.169 Another approach for the reader device 
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calibration is an in-cassette index line containing only printed reporter particles that can 
be used as reference to compensate for the reader-to-reader variations170. 
One method to compensate for variable signal intensities, presented by Response 
Biomedical Corp., called “Ramp ratio”, is to present the intensity ratio of the test line 
and control line. This patented method comprises a separate internal control antibody 
conjugated with reporter particles, which enables the binding of the reporter particles 
to the control line.171 This method compensates for the variable amount of reporter 
particles released from the conjugate pad. 172 
The fitting of the calibration curve from the data points have generally not been 
disclosed by the LFA manufacturers. However, the dose-response of the LFAs is 
similarly dependent of the ligand-binding interactions as are other formats of 
immunoassays. The resulting calibration curve has a sigmoidal relationship with the 
measured signal and analyte concentration173. The fitting with four-parametric logistic 
fit (4-PL) is generally recommended for ligand binding assays 174, 175.    
2.2.4 Working range, signal variation and errors 
The working range, also referred to as the reportable range, means the analyte 
concentration ranges between the lower limit of quantification LLOQ and upper limit 
of quantification ULOQ. It can be determined by using a precision profile (figure 7) 
which is a plot of CV% to represent a back-calculated variation of analyte 
concentrations176. The term dynamic range is often used as a synonym for the working 
range but is not as strictly defined.177  
Fluorescent reporters have been reported to produce wider dynamic range of the assay 
than colloidal gold in LF-format.178  
 




Figure 7. A schematic illustration of the range of quantification in the precision profile 
with a threshold CV of 20 %. The lower limit of quantification (LLOQ) is at analyte 
concentration 0.01 and the upper limit of concentration (ULOQ) is at concentration 10. 
According to IUPAC, the precision is defined as follows: “The closeness of agreement 
between independent test results obtained by applying the experimental procedure 
under stipulated conditions.”78 In the case of immunoassays, the precision of the assay 
is determined by the standard deviation of calculated analyte concentration in replicate 
reactions. With LFAs, the precision is typically limited by factors such as imprecise 
sample volume6 and inaccurate result readout timing82. Furthermore, strip position 
errors may occur because of the imprecision of the binder line dispensing, strip cutting, 
and the test cassette assembly. Depending on the reader device, the positioning error 
can critically affect the test result.179 
In addition to these error sources, the signal intensity variation can be caused by various 
factors, such as storage time of the assay cassettes, reader device calibration errors, and 
a variable amount of reporters released from the conjugate pad. These variations can be 
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with fluorescent reporter have been reported with a CV % less than 10 in assays for 
PSA155 and ractopamine157, and 2–17 in an assay for human neutrophil lipocalin110.  
However, in good conditions (a very controlled environment), a relatively small signal 
variation can be achieved even without compensating the test line signal variation with 
the control line intensity. An example of such a case with a CV % less than 10 has been 
achieved in an assay for HBsAg.111 With a reflectometric measurement of colloidal gold 
particles in an assay for PSA, a CV% of 12 to 17 has been reported.180 
2.3 Commercial LFAs with fluorescent reporters 
Although all the RDTs with a WHO prequalified status use visually detectable reporters, 
there are numerous products with fluorescence-based detection systems for assays 
requiring better sensitivity or quantification. In the United States, the Food and Drug 
Administration (FDA) regulates the selling of medical devices. The in vitro diagnostics 
category covers all the tests that can detect diseases and the conditions of an infection, 
including companion diagnostics, laboratory developed tests, tests used in clinical care, 
home use tests, blood glucose monitoring devices, and drugs abuse tests.181 Therefore, 
practically all LFAs cleared for sale in the U.S. have 510(k) documentation that discloses 
the relevant features of the products. 
2.3.1 Assays with FDA 510(k)-clearance 
The i-CHROMA CRP (k062981) and iFOB (k132167) tests (Boditech Med, South 
Korea) are among the few LFAs with fluorescent reporter particles that have received 
the FDA 510(k) clearance. The tests are intended to be used with the i-chroma reader 
that has been reported to detect Alexa Fluor 647 reporters with laser excitation at 637 
nm wavelength.182, 183 The Quidel Corporation (CA, USA) manufactures LFAs with 
fluorescent UV-excitable reporters for influenza A&B (k153012) to be used with Sofia 
reader that has been re-branded from the cPOC-reader platform by Esterline 
Technologies Corp. The more sophisticated Sofia 2 reader has a touchscreen user 
interface and a built-in CMOS camera instead of a scanning optical sensor 
configuration.184 Assays for RSV (k162911) and influenza A&B (k162438) are available 
for the Sofia 2 platform.  
The UPLink test system was the first commercial LFA platform using UCNP-reporters. 
The system included an FDA cleared test kit for the detection of opiates in saliva67 
(k020371). Test kits were produced for the detection of infectious diseases, such as 
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respiratory syncytial virus185. However, the UPLink test system was discontinued in 2005 
due to lack of commercial success186.  
2.3.2 Assays without FDA 510(k) clearance 
Fluoro-Check™ tests with Eu(III) particles as reporters are available for cTnI, PCT and 
NT-proBNP by Nano-Ditech Corp. (NJ, USA).187 The tests, however, have not received 
FDA clearance and thus are not sold in the United States. The VerOFy® platform with 
LIAM™ reader by Oasis Diagnostics Corporation (WA, USA) is LFA-based point-of-
care system especially intended for saliva samples. The platform uses Eu(III) 
nanoparticles as reporters188, but the capability of time-resolved detection of the 
reporters has not been disclosed. 
UCNP-LF assays for 40 different analytes are being manufactured by Hotgen Biotech 
Co. (Beijing, China). The assays for detecting biowarfare agents, e.g. Bacillus anthracis 
and Francisella tularensis, have been reported to be suitable for use in field conditions.189, 
190 In China, the sales of medical devices and IVD products is regulated by China Food 
and Drug Administration (CFDA). The approval status of the Hotgen Biotech Co. rapid 
diagnostic kits is not available. 
SRI International is developing a biodosimeter by LFAs with UCNP reporters for the 
triage diagnosis of an exposure to ionizing radiation.191 The technology is being 
developed for the Biomedical Advanced Research and Development Authority 
(BARDA) of the United States192 and thus it is unlikely that it will be marketed as a 
commercial product. 
2.3.3 Reporter technologies 
Despite numerous publications describing the use of quantum dots in LFAs160, 193-195, no 
known commercial manufacturers of LFAs with quantum dots were identified. The use 
of upconverting reporter particles with a non-covalently linked biomolecule was 
patented by SRI International196 in 1995, but the commercial exploitation of the 
technology in now less restricted as the patent has already expired. 
LFAs with UCNP-technology are currently being manufactured by Hotgen Biotech 
(Beijing, China) and SRI International (CA, USA). The Hotgen UPT-3A LFA Reader 
has been reported to be used for detecting NaYF4:Yb3+, Er3+ UCNP reporters with a 
diameter of 50 nm.197 The diameters of (YYbEr)2O2S and (YYbTm)2O2S UCNPs 
manufactured by SRI International in 2001 have been reported to be 480 nm.198 The 
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UCNP reporters of two different sizes and morphologies manufactured by SRI 
International are sold under Sunstone® brand by Sigma-Aldrich. Smaller, rod-shaped 
10x60 nm nanocrystals are manufactured with a NaYF4 crystal host lattice and the 
larger, <150 nm diamond-shaped nanocrystals are manufactured with LiYF4-lattice.199 
UV-excitable Eu(III) nanoparticles are sold by Thermo Fisher Scientific under the 
brand name Fluoro-Max™ 200 and by Innova Biosciences Ltd. as a rapid conjugation kit 
with 200-nm diameter Eu(III) particles201. Alexa Fluor™ reporters are different from 
most reporters used in LFAs as they are not particles but organic molecules.202 Alexa 
Fluor™ 647 is one of the largest molecules of the Alexa-series with molecular weight of 
1155 g/mol203.  
2.4 Reader devices for lateral flow assays 
An internet search for commercially available LF readers revealed a total of 67 devices 
(Table 3). From those, 27 have the capability of fluorescence detection and 37 are based 
solely on colorimetric reflectance measurement of the formed test and control lines. 
Only three devices (Magnia Reader, MIAtek® and MICT® analyzer) use non-optical 
detection technology. Six of the devices have been designed to be used with mobile 
devices, such as smart phones or tablets. 
Table 3. Commercially manufactured reader devices for LFAs. Re-branded products 
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2.4.1 Requirements for reader devices 
The specifications of an ideal LFA reader for use in point-of-care diagnostics has many 
similarities with the ASSURED criteria that describes the features of ideal point-of-care 
diagnostic test kits.179, 204, 205 Summarized, the following features are desirable for a 
device:  
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Affordable: The requirement of affordability is highly ambiguous and dependent on the 
target product’s profile of the intended use. Generally, the system should have a positive 
impact on reducing the total costs of health care services. 
Sensitive: The detection sensitivity of the reader device must be adequate enough to 
detect the low analyte concentrations at the range specified for the assay. The 
performance of the detecting system should be stable and consistent.  
Specific: False positive results must not occur due to instrumentation errors such as 
improper calibration or electromagnetic interference. 
User-friendly: The device must be safe to use. The possibilities of electric shock, 
exposure to harmful radiation, harmful chemicals, or biohazardous materials should be 
minimized. The user-interface should be as intuitive as possible with graphical 
guidance. 
Rapid and robust: The device should be ready for use with minimal start up time and 
should be able to process the assay strips at a rate of which patients are incoming for 
testing. The device should tolerate high temperatures and humidity, as for example 
disaster medical assistance teams may have operate in conditions with temperature up 
to +40 °C and relative humidity up to 100 %206, 207. Furthermore, a method for preventing 
fungal growth208 on the optical surfaces should also be considered. The device should 
have warning systems for errors that will prevent the use of the device in unacceptable 
conditions or in cases of electronic or mechanical failures. 
Equipment-free: An ideal LFA reader system can be operated with only minimal 
accessories required. Practically, the assay kit and the reader device must contain all the 
accessories and functions needed for the testing. Some disposable single-use POC 
devices with simple electronic circuits are already on the market. For example, the 
Clearblue Digital test is comprised of a plastic housing with a lateral flow strip and a 
small battery-operated optical system with a LED-light and photodiodes for measuring 
the signal from the test and control lines. More futuristic technology including printed 
electronics with RF powering and even hydrogen fuel-cell technology have been 
demonstrated in applications for POC diagnostics. 209 
Delivered: The device is portable and can be transported to remote locations, for 
example, with a motorcycle. The device must be battery-operated and have the power 
capacity to be operational for the working shift of the user. 
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2.4.2 Principles of optical measurement 
As errors originating from variable lighting conditions and subjective interpretation of 
the test result are well-known problems of the visual interpretation of the LFA test 
results210, the reader devices used to generate the result of the LFA are not affected by 
such errors. The reflectometric measurement, which is the most common detection 
technology in the LF reader devices, measures the decrease of reflected light at a certain 
wavelength area. The light absorbance of the coloured reporter particle appears as a 
darker band in the measurement and the decrease of light is measured by the optical 
sensor.179 
For fluorescent reporters, two measurement strategies are used for the signal detection 
and quantification.  In a scanning measurement, the length of the assay strip moves in 
relation to the optical sensor. In a static imaging measurement, a multi-pixel image is 
generated. Due to the high excitation power requirement, only scanning measurements 
are used in LFAs with UCNP reporters136. The main benefit of the scanning 
measurement over the static imaging methods includes higher detectability of the 
reporter, as the multi-pixel sensors used in the imaging method are not as sensitive as 
PMT or μPMT modules.211, 212 
The static imaging measurement has the capability to analyse two-dimensional images. 
This can be used to recognize errors originating from imaging artefacts, but more 
importantly, it enables the analysis of multiplex arrays printed on the LFA strips102. The 
first publications describing the method utilized flatbed scanners for the image 
acquisition.101, 153 The apparent trend of utilizing the built-in CMOS cameras of smart 
phones for LFA result analysis61, 178, 213 emphasizes the benefits of compact sensor and 
image processing technology with low power consumption. 
Most of the optical measurement methods operate in epi-illumination configuration, in 
which the assay strip is illuminated from the same side as the light sensor. The 
illumination and detection can be either in a confocal or off-axis setting. In the confocal 
setting, the illumination beam and the light sensor are perpendicular to the assay strip, 
whereas in the off-axis setting, the illumination beam and light sensor are in an angle 
and have separate light pathways.179 The trans-illumination configuration is commonly 
used in gel electrophoresis applications with transparent agarose or polyacrylamide 
gels214.  In LFAs, the trans-illumination is less common, but it is used in the Clearblue 
Digital system215 and also demonstrated with Eu(III) nanoparticles216. 
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2.4.3 Sensor technologies 
Optical sensors suitable for use in the LFA readers currently include photodiodes, 
charge-coupled devices (CCD), complementary metal oxide semiconductors (CMOS), 
photomultiplier tubes (PMT), and micro PMTs (μPMTs)211, 212, 217. 
Single sensor photodetectors 
Photodetectors having only one sensor unit are called single sensor photodetectors. 
These include PMTs, μPMTs and different types of photodiodes. Optical plate readers 
used for various formats of immunoassays typically contain a PMT that is used for 
measuring the light modulated by the sample fluids. In the photon multiplier tube, the 
incoming photons activate a cascade of electrons induced by the photoelectric effect 
occurring at the photocathode component of the tube, and the electron flow is amplified 
by dynodes set at incremental voltages.218  
As PMTs are relatively complex devices to manufacture, the physical dimensions and 
the cost of the sensor modules have limited the feasibility of the PMTs in point-of-care 
diagnostics. Microelectromechanical systems in manufacturing have enabled the 
automatized production of more affordable miniaturized versions of PMTs called 
μPMTs212. A μPMTs has the same basic structure containing a photocathode, focusing 
electrodes, dynodes, and the anode as a traditional PMT. With a μPMT sensor, the 
detection module can be manufactured practically as small as a standard photodiode 
sensor (figure 8). Additionally, the requirement of high-voltage circuitry for the gain 
stages of the PMT contributes to the cost of the sensor modules. 
Standard p-n and p-i-n photodiodes are the most affordable photosensors used in 
diagnostic assay readers211, 216. Silicon photodiodes commonly used in smoke detectors 
have also been demonstrated as highly affordable and feasible for a reflectance-based 
LFA reader219. For example, Clearblue digital is a very affordable self-contained LFA 
device sold for pregnancy testing. The test device contains strip assembly with 
transparent backing laminate, LEDs under the strip, and photodiodes on top of the 
strip.215 The ESEQuant LFA reader for UCNP reporters also contains a photodiode 
sensor220, 221. However, the reporter particles used in the assays for ESEQuant LFA have 
a very large, and therefore high, emission intensity136.  
Avalanche photodiodes (APD) used in Geiger-mode are also known as single-photon 
APD (SPAD). The SPAD technology has been reported to have the potential to detect 
single photons as PMTs.222 The technology has also been demonstrated for time-
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resolved fluorometry223, but the usefulness of the technology, as that of the most 
avalanche photodiode sensors, is limited by excessive signal noise level and the 
temperature dependency of the signal gain224. The dynamic range of the APDs used in 
Geiger-mode is limited by the recovery time after each avalanche pulse.222 In theory, a 
reported 1 MHz pulse frequency225 would limit the maximum rate of detected photons 
to one million counts per second.  
 
Figure 8. A schematic representation of A) the PMT and B) μPMT (bottom), and C) the 
photodiode sensors showing I) photocathode, II) focusing electrode, III) dynodes, and 
IV) anode. 
Multipixel photodetectors 
As single sensor photodetectors quantify the total number of photons reaching the 
photoreactive surface of the sensor during a defined time, the multipixel photosensors 
commonly used in imaging applications can provide a two-dimensional intensity 
distribution map. The basic principle of photoreactive surface triggering an electron is 
similar to single sensor photodetectors. However, multipixel photosensors combine a 
large number of miniaturized photoreactive units commonly referred to as pixels.  
I II III IV
A
B C
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Two main types of multipixel photodetector charge-coupled devices (CCD), 
complementary to metal oxide semiconductors (CMOS), are used in various fields of 
industry from consumer electronics to space research226, 227. Cooled CCD camera 
modules are well-suitable for use in high-sensitivity bioimaging applications228, whereas 
the CMOS technology has replaced the older CCD technology in compact imaging 
devices226. CCD photodetectors have successfully been used in LFA readers for detecting 
quantum dot reporters229 and bioluminescent reporters230. 
Current camera units in mobile phones are almost exclusively based on complementary 
metal oxide semiconductors (CMOS) and these applications are discussed in the next 
chapter. Multipixel photon counter (MPPC) is one of the most recent photon counting 
devices. It consists of multiple APD units used in Geiger-mode which enables high-
sensitivity imaging applications in solid-state devices.231 However, no rapid testing 
applications of the MPPC photodetectors have been identified so far. 
2.4.4 Mobile device applications  
As smart phones have gained popularity and become common household commodities, 
the ability to use them for diagnostic testing has been under active study recently. 
Although there are still significant issues with the new point-of-care technologies, the 
capabilities of smart phones can greatly benefit POC testing232, 233. In addition to the 
rapid image processing capability that generates a diagnostic test result, the geolocation 
functionality and wireless data transmission of a smart phone application can provide 
spatio-temporal information for disease monitoring, which can be extremely helpful in 
tracking and controlling epidemics.213, 234 
As the built-in CMOS camera and flash LED are suitable for reflectance-based analysis 
of visible test and control lines, the capabilities of smart phone-based diagnostic devices 
can be expanded by using different extensions containing the needed optics, electronics, 
and cassette holders. The phone-attached modules can be used to provide excitation 
light for fluorescence measurement of the LFAs. Such a system has been reported to 
achieve superior sensitivity and detection range over visually detectable colloidal gold.178 
In addition to high-resolution imaging capability and sophisticated connectivity 
features, software algorithms can also be used to improve the performance of the 
smartphone-based image analysis efficiency235. The management of the test cassettes can 
be integrated into the smart phone application by reading QR codes or RFID tags from 
the cassette to ensure that a correct cassette is being used and the expiry date of the test 
has not passed.179, 189, 236 
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In food-safety applications, the extremely portable smart phone-based applications 
capable of quantitative analysis have been reported to be highly advantageous with the 
apparent limitations set by the sample pretreatment requirements.47 Home-testing with 
a smart phone application also provides an opportunity for conveniently measuring the 
circadian fluctuation of hormones, such as cortisol 63, 161, 162. 
2.5 Feasibility for rapid diagnostic testing 
2.5.1 Characteristics of the point-of-care conditions 
The ASSURED criteria of the WHO outline the desired characteristic of an RDT 
intended for use in resource-poor settings. The acronym stands for “affordable, 
sensitive, specific, user-friendly, rapid and robust, equipment-free,  delivered”.237, 238 In 
terms of evaluating the impact of POC tests on the healthcare, the ASSURED criteria 
may set an artificial barrier for adopting POC tests. Instead of defining a POC test based 
on the used technology, using criteria based on the usefulness of the test in POC settings 
is justified. In different target product profiles (TPP), the requirements for the 
diagnostic product are defined in regard to the characteristics of the user 
environment.239 
In TPP1 (home), the product is used by a lay person in a household environment. In 
TPP2, the tests are done by a minimally trained health worker with no special equipment 
at their disposal. The TPP3 is the most basic level where dedicated instruments are used 
and the tests are done by professional clinical staff. The TPP4 includes the peripheral 
laboratories with lab technicians capable of most routine analysis (e.g. microscopy and 
ELISA). TPP5 is the most sophisticated user environment where in-patients are 
monitored in hospitals.19  
Over-the-counter products sold to lay users, such as pregnancy tests, belong to the TPP1 
which is the only target product profile for products intended for non-professional 
users. The current trend suggests that more products for various analytes will be 
available for home testing.240, 241 Home testing is not only a matter of convenience but 
can be considered a prerequisite for the clinical diagnostic testing in the most resource-
limited settings. The preference of home testing of malaria over having the diagnostic 
test done by a professional at a clinical facility was abundant among rural populations 
due to the distance to the clinical facilities.242 
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Although many of the ASSURED criteria can be fulfilled by LFAs, the shortcomings of 
the technology include the limitations of multiplexing57 and throughput capacity6, and 
the lack of clinical sensitivity with clinically important analytes. For example, there is 
currently only two rapid assays for HCV and no rapid assays for hepatitis-B with a 
WHO prequalification status.24  
2.5.2 Sample matrices 
Various sample materials have been used in clinical LFAs including urine, whole blood, 
serum, plasma, and saliva.6 In point-of-care assays, the ideal sample pretreatment 
should be minimal to achieve a rapid and user-friendly workflow. Therefore, the most 
preferable sample materials for rapid testing would be the ones that require minimal 
effort to prepare for use in LFAs. Capillary whole blood that can easily be collected from 
a finger prick sample, whereas urine and saliva243 are collected using non-invasive 
sampling methods.  
Saliva is a sample type that can be collected by swabs or expectoration.161 Saliva samples 
are popular in LFAs detecting drug abuse66 because of the ease of sampling, for example, 
in roadside testing conditions. Analysis of hormones from saliva samples161 has also 
been investigated intensively, as the small molecular weight hormones are secreted in 
the saliva and can reflect the concentration of the hormone in plasma244. The 
significance of oral fluid sampling for global healthcare is especially emphasized in the 
detection of HIV-antibodies from gingival fluid swabs which has been reported to be a 
cost-effective and non-invasive method in areas with high prevalence of HIV.245 
Urine has been used with LFAs since the appearance of home pregnancy tests. The non-
invasive sampling method and abundance of the sample are obvious factors why urine 
is used in rapid testing. Drawbacks of the urine sampling are the high fluctuation of the 
sample volume that may lead to diluted analyte concentrations and the need for 
concentration pre-treatment before performing the LFA246 in addition to the common 
requirement of collecting the first urine in the morning for the analysis. 
LFAs can also be very useful in scenarios where complicated and invasive sampling 
methods are required. For example, amniotic fluid samples can be taken in emergency 
room scenarios to identify the risk of intra-amniotic inflammation in cases of preterm 
delivery.164 Cerebrospinal fluid collected with a needle from a lumbar puncture can be 
used for diagnosing cryptococcal meningitis.247 For rapid diagnosis of rabies, samples of 
the brains of suspected rabid animals can be tested.248 Venous blood samples require a 
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skilled phlebotomist, sterile needles and the sample collection tubes which in many cases 
may not be available. 
2.5.3 Easy assay procedure 
Sample collection methods impact the assay success in a remarkable way.249 Separate 
bottles of wash buffer may get lost when performing the assay and a temptation to 
substitute the missing buffers with other fluids has been reported to produce false 
positive results250. To avoid problems arising from separate buffer bottles, some 
examples of buffer compartments integrated into the assay cassette have been 
demonstrated.159, 251, 252 Integrated in-cassette sample pre-treatment functions have been 
reported in addition to conventional use of blood filter membranes. For example, a 
method for in situ lysis of blood cells in the LFA-cassette has been patented by Rapid 
Pathogen Screening Inc.253 Furthermore, a sophisticated method using stimulus-
activated iron oxide and gold nanoparticle system for sample enrichment and 
purification for malarial HRP2-protein has been reported.254 
Assays requiring multiple steps with additions of different fluids in a specific order are 
generally not accepted in POC conditions. In the WHO prequalification guidelines for 
HIV-antibody assays, the ease of performance is scored according to the relevant 
parameters constituting the assay procedure. These parameters include a number of 
steps in the procedure, clarity of kit instructions, kit and packaging labelling, a number 
of reagents that are needed to prepare, stability of diluted reagents after opening, and a 
number of required items not provided in the kit.255 
Currently, embedded on-cassette flow control mechanisms are more complicated to 
produce than conventional LFA strips, as special liquid distribution functions are 
required of the assembly line. A relatively inexpensive and robust technology for 
sequential introduction of fluids into an LFA strip has been described by using simple 
one or two-dimensional fluid pathways256, 257 for capillary-driven assay devices, but the 
patenting of the technology258 restricts its commercial use.  
The ASSURED criteria do not state the time for completing the assay. However, all the 
RDTs for HIV antibodies or malaria having the WHO prequalification status can be 
completed within 10 to 31 minutes 255, 259. This can be considered as a benchmark for 
other RDTs for infectious diseases, as the use of RDTs for HIV and malaria have been 
successfully scaled up in the most demanding conditions35. 
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The total time from sample to results consists of sample pre-treatment and the 
incubation of the initiated immunochromatographic reaction. The incubation time of 
the reaction is defined by the liquid flow rate in the assay membranes and the total 
volume of the fluids passing through the membranes as described in chapter 2. Although 
a major impact on the global HIV diagnostics has been achieved by rapid point-of-care 
tests hurdles, the standardization, regulatory affairs and human resource management 
have been recognized to limit the cost-effectiveness of the HIV testing programmes.260 
2.5.4 RDTs and biosafety 
As blood samples are often used in LFAs, the capability of the assay cassette to contain 
the assayed fluids without leakages is essential to avoid the exposure to biohazardous 
material. Safety must also be considered in the sample collection procedure. As the 
blood transfer devices must have sufficient volumetric accuracy, the unintentional 
release of blood must be minimized in order to avoid healthcare workers’ exposure to 
blood.261 
When discarding the used assay cassettes and or expired test kits, potential harmful 
contents must be considered. For example, cadmium in the quantum dots may  present 
a potential health and environmental hazard194. Sodium azide (CAS nr. 26628-22-8) 
often used in buffer solutions is classified as harmful to the environment and classified 
as hazardous waste by US Environmental Protection Agency262. Concerns have also been 
generally expressed on nanoparticle waste in the environment. The potential toxicity of 
nanoparticles relates to their small size which allows them to migrate through biological 
structures, such as cell nuclei or blood–brain barrier.263-266  
2.5.5 Cost of the assays 
According to a survey conducted in Tamil Nadu, India, people in the poorest, “Base of 
the Pyramid” socio-economic population group are willing to pay 50–100 INR (1.3 €) 
for a diagnostic test.267 Currently, only simple LFAs and flow-through RDTs can be 
provided for the POC market within this price range. An example of the lack of 
affordability, which is an unmet ASSURED criterion, is the POC testing for tuberculosis 
(TB). At the moment, the only POC test with sufficient sensitivity for managing 
multidrug-resistant TB epidemics is the Xpert MTB/RIF (Cepheid, Sunnyvale, CA, 
USA) nucleic acid amplification test (NAAT)268. The currently available LFAs for TB are 
sensitive enough to be used only with a growth medium culture269. In this case, the LFAs 
fail to meet the sensitivity requirement of the ASSURED criteria, as the Xpert MTB/RIF 
is considered too expensive with the $9.98 USD price for assay cartridge within eligible 
Review of the literature 
53 
 
countries.270 According to a simulation model, a cheap rapid test suitable for mass 
screening would have a significant impact on curbing drug-resistant TB epidemics. 271 
Quantitative LFA technologies have been reported to be affordable enough for 
manufacturing in low-income settings.  The UCNP technology with a small stand-alone 
reader has been demonstrated to be feasible for use in remote, low-resource locations 
for the testing of Schistosoma circulating anodic antigen.220 Another UCNP-based LFA 
for anti-HBV antibodies has been described as affordable and reported to have analytical 
sensitivity better than ELISA, which demonstrates that the technology is well-suited for 
serological testing.272 The usefulness of such a serological test would be most apparent 
in monitoring antibody formation after a HBsAg-vaccination. 
The production of a typical LFA test kit with a visually interpretable result has been 
estimated to cost $0.38 USD in total.13 Depending on the additional price components 
of the products, such as logistics, personnel, marketing, and profit margins, the price of 
the LFAs can match the needs of low-income settings. Even though the assay kits with 
a disposable immunochromatographic strip are valuable because of the stand-alone 
capability, they do not have the versatility enabled by quantification. In another 
approach to permanent integrated instruments that require maintenance, significant 
complications are expected with the maintenance and up-keep. Considering the 
drawbacks of these strategies, a strategy with disposable assay cassettes and a simple 
reader device appears to be promising for low-income settings.273 
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3 AIMS OF THE STUDY 
The overall aim of this thesis was to examine the use of Eu(III) nanoparticles and 
UCNPs as reporters in LFAs, and to evaluate the potential of improving assay sensitivity 
and the capability to produce quantitative LFAs. 
More specifically, the aims were: 
I To evaluate the potential of improving the analytical sensitivity of LFAs by 
replacing the colloidal gold reporter particles with fluorescent 
Eu(III)nanoparticles and compare time-resolved, pulse-excited, and continuous 
detection modes. 
II To examine the compatibility of blood samples containing different 
anticoagulants with an LFA using Eu(III) nanoparticles or UCNPs as reporters. 
III To demonstrate the quantification potential of an LFA with UCNP reporters with 
a clinically relevant analyte, and compare the assay performance against a 
conventional ELISA using real patient samples. 
IV To compare the LFA platform with a point-of-care assay platform with 
microparticles used as the solid phase.
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4 SUMMARY OF MATERIALS AND METHODS 
A brief summary with some additional information is presented here. A more detailed 
description of the materials and methods used in this study can be found in the original 
publications (I-IV). 
4.1 Reporter particles 
4.1.1 Bioconjugation of reporter particles with binder molecules 
Upconverting nanoparticles and Eu(III) nanoparticles were covalently bioconjugated 
with monoclonal antibodies using NHS-EDC chemistry.  
Colloidal gold was passively conjugated with monoclonal antibodies by the inherent 
protein-binding feature of the gold particles.  
4.1.2 Upconverting nanoparticles 
The upconverting nanoparticles used in the assays for PSA and cTnI (II) were 
synthesized in-house, coated with silica layer, and reactive carboxylic acid groups were 
induced on the particle surface. The particles (figure 9) used in the MxA assay (III) were 
manufactured by Kaivogen Oy (Turku, Finland).  




Figure 9. Transmission electron micrograph of the NaYF4:Yb3+, Er3+ UCNPs 
manufactured by Kaivogen Oy. JEM-1400+ TEM, 80 kV (JEOL, Tokyo, Japan). Image 
courtesy of Kaivogen Oy, Antti Pihlava. 
The carboxyl-activated UCNPs were bioconjugated with mAbs using 2 mM EDC and 
30 mM sulfo-NHS as described earlier by Kuningas et al.274   
For the PSA-assays (II) mAb-5A10275 was conjugated with upconverting nanoparticles 
using 83 μg of mAb per 1 mg of UCNPs in the reaction. For the cTnI-assays (II), mAb-
8I7 (International Point of Care Inc., Toronto, ON, Canada) was conjugated using 83 
μg of mAb per 1 mg of UCNPs. For the MxA assay (III), mAb-AFI7B3 (Institute of 
Clinical Medicine, University of Eastern Finland) was conjugated using 41.5 mg of mAb 
per 1 mg of UCNPs. 
4.1.3 Eu(III) nanoparticles 
The Eu(III) nanoparticles used in the assays (I-II) were polystyrene spheres containing 
Eu(III) chelates with product name OptiLink (Seradyn, Indianapolis, IN, USA). The 
particles were shipped with activated carboxyl groups on the surface. The 
bioconjugations were done as described earlier by Kokko et al.276  and Soukka et al.277. 
For the cTnI assay, mAb-8I7 and, for the PSA assay, mAb-5A10 were conjugated using 
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mAb concentration of 0.5 g/L in the reaction at pH 6.1. For the bio-BSA assay, 
streptavidin was conjugated at a concentration of 2 g/L. 
4.1.4 Colloidal gold 
The colloidal gold used in the assay for biotinylated bovine serum albumin (bio-BSA) 
(I) was streptavidin-conjugated colloidal gold particles with a diameter of 40 nm and an 
optical density of 10.3 AU at 520 nm manufactured by British Biocell International 
(Cardiff, UK). 
For the PSA-assays (I-II), mab-5A10 was diluted in 20 mM sodium borate buffer pH 
9.0 to a total volume of 1 mL with concentration of 0.188 g/L. and added to 5 mL of 
colloidal gold solution (Ani Biotech, Vantaa, Finland) with pH previously adjusted to 
9.0. 
4.2 Preparation of LFIA strips 
4.2.1 Strip membrane assembly 
A 25 mm wide nitrocellulose membrane HF180 Hi-Flow plus (Merck, Ireland) (figure 
10) was pasted on a 70 mm wide plastic adhesive laminate (G&L Precision Die Cutting) 
previously cut into 20 cm cards. The feed pad was 8 (I) or 16 mm (II) wide GFCP203000 
glass fibre membrane (Merck) or pre-blocked 10 mm wide polyester membrane PT-R1 
(mdi Membrane Technologies, Ambala, India). The feed pad was pasted on to the 
backing laminate with a 2 mm overlap with the nitrocellulose membrane.  
Wicking pad of CFSP223000 cellulose membrane (Merck) cut to the width of 27 mm 
was pasted on to the distal end of the backing laminate overlapping 2 mm with the 
nitrocellulose membrane. 
Dedicated blood filter membranes or sample pads were not used in the experiments as 
unprocessed whole blood was not used, and the assays were done by dipping the strips 
in microtiter wells instead of using plastic strip holder cassettes. The fluorescence 
spectra of the HF180 nitrocellulose membrane (Merck) were scanned using Varian Cary 
Eclipse fluorescence spectrometer (Varian Scientific Instruments, Mulgrave, Australia). 
A scan representing a typical fluorescence measurement conditions with an assumed 20 
nm Stokes’ shift of a reporter was done using synchronical emission measurement at 
excitation wavelength + 20 nm. Another fluorescence scanning was done with a static 
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excitation at 350 nm and a scanning emission measurement at range 400–650 nm using 
a 5 nm slit. 
 
Figure 10. Scanning electron micrographs of nitrocellulose membrane HF180 Hi-Flow 
plus (Merck, Ireland). A) Porous side, top view, 400-fold magnification; B) porous side, 
top view, 1000-fold magnification; C) side cut view, 300-fold magnification; D) side cut 
view; 1200-fold magnification. In pictures C and D, the backing film can be seen under 
the porous nitrocellulose matrix. The horizontal lines visible in the backing film indicate 
the cutting direction of the membrane sample. Due to the cutting direction the porous 
material has not been collapsed in the cutting process. In picture D the asymmetric 
structure of nitrocellulose matrix is visible. The pore size is smaller on the side of the 
backing than on the air side.  Images courtesy of prof. Martti Toivakka (Center for 
Functional Materials, Åbo Akademi University). 
4.2.2 Dispensing of binder lines and strip cutting 
Monoclonal antibodies were used as capturing reagents on the test line in each of the 
published LFIAs with the exception of the bio-BSA assay. The control lines were 
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dispensed using 0.6 g/L rabbit anti-mouse polyclonal antibodies (Dako, Denmark) in 10 
mM citrate-phosphate buffer pH 5.0 using Linomat 5 line dispenser (Camag, 
Switzerland) with a flow rate of 250 nL s-1 and dispensing rate of 1 μL cm-1. 
For the bio-BSA assays, the test line was dispensed with 4 g/L streptavidin (Bioreba, 
Reinach, Germany) in 10 mM in citrate-phosphate buffer pH 5.0 and the control line 
was dispensed with 10 mg/L bio-BSA diluted in the same buffer. For the PSA assay, 
mAb-H117 (University of Turku) was dispensed in concentration 1.5 g/L (I) or 0.45 g/L 
(II)  
For the cTnI assays, the test lines were dispensed with 0.6 g/L mAb-4T21-19C7 (Hytest) 
for the single capture format or with a mixture of mAb-4T21-19C7 and mAb-4T21-
MF4 (Hytest), each in concentration of 0.3 g/L.  For the MxA assay (III), the test line 
was printed with 0.6 g/L mAb-AFI10G10 (Institute of Clinical Medicine, University of 
Eastern Finland). All the monoclonal antibodies were diluted in 10 mM Tris-HCl pH 
8.0 for dispensing. 
After dispensing the binder lines, the membranes were incubated in +35 °C for two 
hours. The membrane cards were cut into the 4 mm (I) or 5 mm wide (II-III) strips 
using a desktop paper cutter (I-II) (Ideal 105, Krug & Priester, Balingen, Germany) and 
a dedicated CM4000 guillotine cutter (III) (Biodot Inc., Irvine, CA, US) before 
performing the assays. 
4.3 Sample materials 
4.3.1 Buffer-based calibrators 
All the published assays were initially optimized using the respective analyte molecules 
spiked in 7.5 % BSA in tris-saline-azide (TSA) buffer pH 7.4. In PSA assays (I-II), the 
calibrators were prepared by diluting recombinant prostate-specific antigen produced 
in a baculovirus expression system278. In the cTnI assays (II), calibrator solutions were 
diluted from purified human cTnI-T-C complex (Hytest). 
4.3.2 Serum and plasma 
For serum samples (I-II), the blood was collected in tubes containing separation gel and 
clotting activator (VenoSafe VF-108SAS, Terumo). For plasma samples (II), the blood 
was collected in K3EDTA tubes (Venoject VT-100STK, Terumo) or Li-heparin tubes 
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(VenoSafe VF-109SHL, Terumo). The samples were produced with centrifugation 
according to the user manuals of the blood collection tubes. Calibrator solutions for PSA 
assays (II) were prepared by diluting recombinant prostate-specific antigen and, for 
cTnI assays (II) by diluting human cTnI-T-C complex in serum and plasma. 
4.3.3 Whole blood 
In the LFIA for MxA whole blood (III), the clinical samples were collected in non-
specified Li-heparin tubes and diluted to 1:20 in hypotonic buffer solution to lyse 
hemocytes and used in the assay without further preparation steps. A calibrator solution 
was prepared by diluting recombinant MxA279 into diluted whole blood. 
4.4 LFIA procedure  
4.4.1 Fluid absorption sequence 
The fluids were absorbed into the LFA strips from polypropene microtiter plate wells 
(Figure 11). In the assays without pre-incubation of reporter bioconjugates and sample 
fluid (I), the first well contained only the sample fluid and reaction buffer. After 
absorption of the sample fluid, the strips were transferred into wells containing the 
reporter bioconjugate and, after complete absorption, into wells with wash buffer 
solution. In the assays with pre-incubation step, the first well contained a mixture of 
reporter bioconjugate, sample fluid and reaction buffer (II, III). After absorbing the 
fluid, the strips were transferred into wells with wash buffer solution. The compositions 
of the used buffers are presented in table 4. 
Table 4. The buffer solutions used in the LFAs. 
Assays Reaction buffer Wash buffer 
bio-BSA & PSA 
10 mM HEPES, pH 7.4, 270 mM NaCl, 1 % 
BSA, 0.5 % Tween-20 
same as reaction buffer 
cTnI 
10 mM Na2HPO4/NaH2PO4, pH 7.4, 135 mM 
NaCl, 1 % BSA, 0.5 % Tween-20, 0.06 % Bovine 
γ-globulin 
same as reaction buffer 
MxA 
0.9 M NaCl, 60 mM K2HPO4, 12 mM KH2HPO4, 
pH 7.4, 3 % BSA, 0.3 % NaN3, 0.3 % Tween-20 
10 mM Tris-HCl, pH 8.5, 270 mM 
NaCl, 1 % BSA, 0.5 % Tween-20 
 
 




Figure 11. A schematic presentation of the fluid absorption procedure by dipping the 
assay strip into microtiter wells. 
4.4.2 Measurements and data interpretation 
The signal intensities of the assay strips were measured either by using a scanning reader 
device or by a photographic procedure. The assays with Eu(III) nanoparticles (I and II) 
were scanned with VictorX4 plate reader (Perkin Elmer, Waltham, MA, USA) using a 
340-nm excitation filter and 615-nm emission filter. The delayed, time-resolved 
measurements were done using a 400-μs delay time, a 400-μs counting window and a 
duty cycle of 1000 μs. The instant detection measurement was otherwise similar but 
without the 400-μs delay time.  
In the assays with Eu(III) nanoparticles used as reporters, the signal of the test and 
control lines was calculated from a single data point and, as with the VictorX4 plate 
reader, the measurement area covered by a single scanning point was approximately 3 
mm in diameter. Therefore, the whole width of the test line was covered by a single 
scanning point making the integration of multiple scanning points unnecessary. 
Fluorescence imaging of the Eu(III) nanoparticles (I) was done by using a Canon 
Powershot SX130 IS digital camera (Canon) attached to a laboratory stand and clamp, 
and taking the picture through a D615/25 bandpass filter while illuminating the assay 
strips with a handheld ultraviolet lamp (Spectroline, Westbury, VT, USA).   
The signals produced by visually detectable colloidal gold particles were measured using 
reflectometric scanning methods. A USB flatbed scanner (Canoscan 9900F, Canon, 
Tokyo, Japan) was used to generate a photograph of the assay strips and the reflectance 
intensity profiles were generated with ImageJ software (National Institutes of Health, 
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Bethesda, MD, USA) (I). Another method of reflectometric measurement of colloidal 
gold (II) was demonstrated using ChemiDoc MP gel imaging device (Bio-Rad, Hercules, 
CA, USA) and the proprietary Image Lab software.  
Assay strips with upconverting nanoparticles were scanned using a modified274, 280 Plate 
Chameleon (Hidex Oy, Turku, Finland) (II) or UPCONTM Reader (Labrox Oy, Turku, 
Finland)(III). The area covered by a single scanning point was smaller than the width 
of the binder lines, thus the signals obtained from the location of the test line were 
summed from a scanning range of 1.5 mm.  
The calibration of the assay was done by fitting the data points obtained with the 
calibrator solutions with a four-parametric (4-PL) logistic fit (4), where A1 is the initial 




The control line signal was used to define the location of the test line printed at 6 mm 
distance from each other. A scanning area of 1.5 mm at the location was used to calculate 
the average signal of the binder line area (figure 12).   
 
Figure 12. Schematic illustration of the peak integration of the test and control line 
signals. The control line (C) peak is used to locate the test line (T). The total area of the 
peak is integrated from the 1.5 mm scanning area. 
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4.5 Microparticle-based assay platform 
To study simple alternatives for nitrocellulose-based LFAs, a simple and affordable 
platform was developed for point-of-care conditions. Instead of having the capture 
antibodies bound on a nitrocellulose membrane, the capture antibodies were 
conjugated with 140 μm polystyrene microparticles that first react with soluble 
immunoreagents and are then collected on a filter mesh to be measured. 
4.5.1 Assay cassette  
A simple syringe-operated assay cassette (figure 13) was designed using AutoCAD 
software (Autodesk Inc., CA, US). Initial prototype stages of the design were produced 
with stereolithographic 3D printing. The finalized design was produced by injection 
moulding. The cassette body was moulded from polypropene and the revolving optical 
cap was moulded from poly(methyl methacrylate) (PMMA). A gasket ring to support 
the filter mesh was injection moulded from transparent thermoplastic urethane (TPU). 
A cover cap for the reaction chamber was manufactured by casting polydimethyl 
siloxane (PDMS) Sylgard 184 (Dow Corning, Midland, MI, US). 
 
Figure 13. A schematic illustration of the main parts of the assay cassette. (A) Cassette 
body, (B) revolving optical cap, (C) gasket ring to support the filter mesh, and (D) 
reaction chamber cap. 
4.5.2 Capture microparticle bioconjugation 
Dynoseeds TS140 (Microbeads AS, Skedsmokorset, Norway) polystyrene 
microparticles were passively coated with crosslinked streptavidin. The crosslinking of 
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increased stability and binding capacity281. The streptavidin-coated microparticles were 
incubated in a mixture of biotin-linked anti-cTnI antibodies mAb4T21-19C7, 
mAb4T21-MF4, and mAb-4T21-916 to produce capture particles with minimal 
interference occurring from anti-cTn autoantibodies282.  After the conjugation with 
biotinylated antibodies, the non-conjugated antibodies were washed off of the 
sedimentation of particle by centrifugation and resuspending in 8 % NaCl solution. 
4.5.3 Assay procedure 
First, 140 μl of sample fluid, 100 μl of assay buffer, 2100 capture microparticles in 14.5 
μl volume, and 500 ng of mAb-8I7-UCNPs in 10 μl volume were added to the reaction 
chamber and incubated for one hour in 500 rpm shaking. After the incubation, the 
reactions were washed by opening the rotating optical cap to allow liquids to pass 
through the filter mesh. Negative pressure was applied to the suction channel orifice by 
a syringe while a pre-filled wash buffer pouch with 3 ml of wash buffer was attached to 
the buffer inlet of the cassette. 
4.5.4 Signal detection 
The UCNP signals from the immune complexes captured on the microparticles were 
measured from the detection chamber using a portable custom fluorometer instrument 
(DesignInnova, New Delhi, India). 
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5 SUMMARY OF RESULTS AND DISCUSSION 
5.1 Reporter particles 
5.1.1 Colloidal gold versus luminescent reporters 
The detectability of the optical reporter particles (I) used in LFAs contributes to the 
achievable assay sensitivity with two major factors: 1) The ability to generate enough 
signal to be detectable by the optical sensor and 2) the ability to exclude non-reporter-
specific light emission from the detection. These two features, however, do not define 
the sensitivity of LFAs using fluorescent reporters, as the non-specifically bound 
reporter particles commonly cause a background signal that cannot be excluded by 
optical detection systems.  
With colloidal gold, the optical detection is based on reflectance measurement, in which 
the intensity of the coloured lines on the assay strips are measured by the decrease of the 
reflected light. The reflectance of the coloured line is relative to the reflectance of the 
surrounding area on the nitrocellulose membrane. An 8-bit grayscale image allows each 
pixel to have 256 intensities, of which value 255 represents white and value 0 black. 
When the blank assay strip signal is calibrated into being bright white, a completely non-
reflective area on the strip would result in a grayscale value 0. Simplified, the 
reflectometric measurement detects non-reporter-specific background light, from 
which the decrease of reflected light is translated into the reporter-specific signal. 
Reflectometric measurement is prone to errors due to dust speckles, remnants of 
coloured sample fluids, or uneven illumination of the strip surface. Such factors decrease 
the amount of reflected light and can be interpreted as reporter-specific signals. With 
luminescent reporters, the non-reporter-specific signals commonly originate from the 
autofluorescence of the used material or the inefficiency of the optical detection system 
in blocking the light of the excitation light source. 
5.1.2 Measurement mode of Eu(III)-nanoparticles 
The luminescence of the Eu(III) nanoparticles can be measured in a time-resolved 
manner, which further reduces the residual non-reporter-specific fluorescence that is 
not excluded by the spectral resolution achieved by the Stokes’ shift. The effect of the 
measurement mode on the analytical sensitivity was shown to affect the amount of non-
specific fluorescence originating from the assay materials (I). 
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A significant advantage of the Eu(III) nanoparticles is the long Stokes’ shift that enables 
very efficient spectral resolution of the excitation and emission light. The excitation light 
was filtered to pass only a 40-nm range with a centre wavelength of 340 nm in 
measurements done with a fluorescence reader. 
The significance of the Stokes’ shift was even more evident in the fluorescence 
photography procedure. A continuous, non-filtered UV excitation by a handheld UV 
lamp with a peak wavelength at 365 nm (figure 14) was used with bandpass emission 
filter passing only a 25 nm range with a centre wavelength of 615 nm. Most non-
reporter-specific fluorescence was excluded by the spectral resolution, but a measurable 
fluorescence was still observed from the nitrocellulose membrane. Thus, the 
detectability of the reporter particle signal was not as high as by using pulsed excitation 
measurement. 
 
Figure 14. Emission spectrum of the handheld UV-lamp (Spectroline ENF-280C/F) 
with a peak wavelength at 365nm. Measured with Ocean Optics HR4000 UV-VIS 
spectrophotometer. 
In addition to the spectral resolution, the non-reporter-specific background signal could 
be further decreased with time-resolved measurement. The effect of time-resolution was 
tested with three detection modes: 1) Delayed time-resolved measurement, 2) instant-
detection time-resolved measurement and 3) continuous excitation imaging.  
The instant-detection time-resolved measurement mode resulted in analytical 
sensitivities (PSA assay 0.08 μg/L, bio-BSA assay 0.03 μg/L) that were very close to the 
sensitivities achieved with delayed time-resolved measurement mode (PSA assay 0.07 
μg/L, bio-BSA assay 0.02 μg/L) (I). This suggests that the non-reporter-specific 
fluorescence constitutes only a small portion of the total fluorescence of the reporter 
during the time of the measurement cycle between the excitation pulses. Thus, the use 
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of delay time gate after an excitation pulse provides only a minor improvement in the 
detectability of the Eu(III) nanoparticles in LFAs.  
The practical implication of this result encourages the consideration of using Eu(III) 
nanoparticles with small portable reader devices equipped with pulsed UV-LED 
excitation, as the complicated mechanism for the temporal gating of the emission signal 
is not needed. The spectral resolution combined with pulsed excitation enables the 
utilization of the large Stokes’ shift and the long lifetime of fluorescence in the Eu(III) 
nanoparticles.  
5.1.3 Measurement of UCNP-reporters 
A major advantageous feature of the UCNP detection was the capability to exclude non-
reporter-specific fluorescence from the assay measurements (II & III). The scanning 
profiles of the assays with UCNPs used as reporters indicated that the background 
fluorescence originates from the reporter particles that have been retained on the 
nitrocellulose matrix. Therefore, the mobility of the UCNPs in the nitrocellulose was 
identified as a key factor for achieving high-sensitivity LFAs.   
As the upconversion process requires the absorption of two or more low-energy 
photons to emit a single photon of higher energy, the emitted energy increases with a 
non-linear dependency on the excitation light. Therefore, the capability of the UCNPs 
to generate sufficient signal to be detected by an optical sensor is dependent on the 
intensity of the IR excitation.283 The estimated excitation power densities achieved by 
the measurement instruments used in the experiment were approximately 50–100 
W/cm2. Similar excitation power densities have been reported also for larger, 0.48 μm 
UCNPs.198 The reported saturation level of the excitation power dependency on the 
quantum yield is above 150 W/cm2,136 which suggests that, with a higher laser diode 
output and more accurately focused optics, higher reporter signal intensities can be 
achieved. However, with an excitation power density of 100 W/cm2, the strips were 
likely to burn if there were dust speckles or red colour from the blood sample in the 
assay strip.  
The potential of the UCNPs for achieving quantitative LFAs was observed by correlating 
UCNP-LFA for MxA results with an ELISA test as a reference (III). Interpreting the 
assay result by using the test line per control line (T/C) intensity ratio instead of the test 
line signal alone compensated for variations in UCNP amounts migrating in the 
analytical membrane. This is especially helpful in LFAs where the release of the reporter 
particles from the conjugate pad is inconsistent. 
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5.1.4 Performance of lateral flow assays 
Analytical sensitivity  
The analytical sensitivities achieved in the study by using colloidal gold, Eu(III) 
nanoparticles, and UCNPs in assays for bio-BSA, PSA, cTnI and MxA are presented in 
table 5. Based on the results, the fluorescence-based reporter technologies, Eu(III) 
nanoparticles, and UCNPs produced assays with a higher sensitivity than assays with 
colloidal gold (I-II). Whether the Eu(III) nanoparticles or the UCNPs will generally 
result in higher analytical sensitivity remains inconclusive (II), as the assay sensitivity 
was limited by a background signal originating from non-specifically bound reporters. 
Table 5. The analytical sensitivities of the LFAs performed in the study. 
Analyte Reporter Sample matrix 
Analytical sensitivity 
[μg/L] 
bio-BSA colloidal gold Buffer 6.10 
bio-BSA Eu(III) nanoparticles Buffer 0.02 
PSA colloidal gold Buffer 0.44 
PSA Eu(III) nanoparticles Buffer 0.196 
PSA upconverting nanoparticles Buffer 0.556 
cTnI Eu(III) nanoparticles Serum 2.039* 
cTnI upconverting nanoparticles Serum 0.041 
MxA upconverting nanoparticles Buffer 1.669** 
*High variation in no-analyte (blank) reactions 
** rMxA concentration of the diluted sample fluid 
As the LFA procedures used for the studies were optimized for use with batches of 30–
100 assay strips handled simultaneously, these results do not necessarily reflect the 
actual performance of a single, stand-alone assay cassette in a commercialized 
diagnostic assay kit with dried reporters and a plastic strip housing. Furthermore, as the 
assays were performed in strictly controlled laboratory conditions, the performance of 
the assay in realistic point-of-care conditions may be affected by factors such as 
humidity and heat. 
Clinical sensitivity and specificity of the MxA-assay 
The UCNP-LFA platform was demonstrated to be feasible in an actual clinical 
application for the indirect measurement of IFNβ therapy response monitoring in 
multiple sclerosis (MS) patients (III). The quantitative results of the assay were 
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interpreted by using a MxA cut-off level of 100 μg/L to identify treatment responders 
and non-responders. Tested with 36 clinical patient samples, the clinical sensitivity of 
the UCNP-LFA for MxA was 96 % with the specificity of 89 % when a routine ELISA 
procedure was used as a reference. 
The UCNP-LFA for MxA was seen as feasible for use in routine clinical laboratory settings 
where ELISAs are typically done. The main benefit achieved with the UCNP-LFA was a 
significant decrease in the performing time of the assay procedure. The ELISA procedure 
is carried out in two days with an overnight incubation where the UCNP-LFA can be 
completed within two hours. The MxA assay was the only assay in the study that considers 
pre-treatment procedure and its effect on the analytical sensitivity.  
5.2 Assay platforms 
5.2.1 Lateral flow assay platform 
As the lateral flow assay platform is practically dependent on the nitrocellulose 
membrane, the membrane characteristics are very significant factors that define the 
limitations of LFAs. As stated by the Washburn equation and the Darcy’s law, the liquid 
flow speed in nitrocellulose depends on the pore diameter of the nitrocellulose matrix, 
viscosity of the sample, hydrophobicity of the matrix surface (contact angle), and the 
surface tension of the fluid. For this reason, the liquid flow speed in the LFAs can only 
be adjusted by selecting nitrocellulose membranes rated with different flow speeds or by 
introducing barriers to restrain the liquid flow. The HF180 nitrocellulose membranes 
(Merck) used in the studies were among the slowest membranes available with a wicking 
rate of 180 s / 4 cm. 
A slow nitrocellulose membrane was selected to achieve maximal time for forming of 
the immunocomplexes on the capture lines, thus assuming increased assay sensitivity 
(I-III). Furthermore, the printing of the capture lines resulted in thinner capture lines, 
as the biomolecules used for the capture line could not disperse in the nitrocellulose as 
much as in a faster membrane before the solvent had evaporated.  
The steps of the LFA procedures in this study included dispensing the sample fluid, 
reporter solution, and wash buffer into the microtiter wells. Subsequently, the assay 
strips were dipped in the fluids in sequential order and allowed to absorb the fluids 
completely. The process constituted of approximately 5–10 minutes of hands-on time, 
as the strips had to be allowed to absorb the fluids completely before moving them into 
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the consecutive microtiter well. When the assay strips were in the wash buffer, the assay 
was left unattended until the measurement step which was performed after the strips 
had dried completely (i.e. at least two hours). For the measurement step, the assay strips 
were attached to a strip holder tray and measured with a reader compatible with the 
reporter technology. The total required time for the assays performed in the study was 
typically 2–4 hours. The limited liquid capacity and increased assay time set a limit for 
the wash buffer used in the assay. Therefore, non-specifically-bound reporters retained 
at the assay strip may limit the assay sensitivity. 
Nitrocellulose membrane characterization (previously unpublished additional data) 
The fluorescence characteristics of the HF180 nitrocellulose membrane indicated that 
the membrane has its most significant short Stokes’ shift fluorescence peaks at 
wavelengths shorter than 520 nm (figure 15A). With a static excitation at 350 nm, the 
scanning indicated that the autofluorescence with UV-excitation spans throughout the 
whole scanning range (figure 15B). The substantial autofluorescence peak observed at 
550 nm has also been reported by Swanson et al.112. These observations confirmed that 
a significant part of the autofluorescence originating from the nitrocellulose is not 
eliminated by the spectral resolution as seen in the fluorescence photography of Eu(III) 
nanoparticles. The autofluorescence of the nitrocellulose can be problematic, especially 
with reporter technologies having insufficient Stokes’ shift to efficiently resolve the 
reporter-specific signal from non-specific fluorescence by optical filters. 
 
Figure 15. Fluorescence spectrum of the HF180-nitrocellulose membrane. A) Emission 
detected synchronically at excitation wavelength + 20 nm. B) Emission scanning with 
constant excitation at 350 nm. 
The size distribution observed with the Hg porosimetry analysis (figure 16) indicated 
that the average pore size was 4 μm, but a significant portion of the pores have a diameter 
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located at the bottom of the nitrocellulose matrix (figures 5&10), it is likely that the 
liquid flow speed is not constant throughout the depth of the matrix. A situation where 
the liquid flow would be slower at the bottom of the matrix would be likely to cause 
reporter particles to be retained in the nitrocellulose membrane. 
 
Figure 16. Mercury porosimetry analysis graph of the Hi-Flow Plus HF180 
nitrocellulose (Merck). Histogram indicating the size distribution of the nitrocellulose 
pores (left y-axis). Cumulative pore volume indicated with a curve (right y-axis) 
5.2.2 Microparticle-based assay platform 
As in the LFAs, the formed immunocomplexes are bound to a stationary location in the 
binder lines and the capture microparticles are free to move in the reaction mixture of 
the microparticle-based assay. (IV) The collection of the capture microparticles on the 
filtration mesh for the reporter signal measurement could efficiently collect the capture 
microparticles (figure 17). This feature enables favourable reaction conditions that allow 
the immunocomplex to be formed for a longer time on to the capture surface, and 
mixing to improve reaction kinetics. However, the variation of the amount, orientation, 
and location of the capture microparticles in the detection chamber may present 
variation in the assay results.  
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Figure 17. A schematic illustration of capture microparticles collected in the 
measurement chamber to be measured through an optical cap. 
The performance of the microparticle-based assay platform was demonstrated with a 
cTnI assay done with cardiac troponin ITC complex diluted in assay buffer. The assay 
included a mixing of the analyte solution, capture microparticle solution and mab-8I7-
UCNP solution, incubation for one hour, and a washing step prior to the measurement. 
With a total assay time of less than 90 minutes and a hands-on time of less than five 
minutes, a limit of detection of 19.7 ng/L was achieved.  
As the manufacturing process of the microparticle-based platform requires specific 
injection-moulded cassettes, nylon filters, optical caps, gasket rings, buffer pouches, and 
separate syringes to drive the wash step, significant assembly is required for 
manufacturing complete test kits. Therefore, the manufacturing price is unlikely to be 
competitive with highly automatized LFA manufacturing lines. The microparticle-
based assay, however, may have a niche of products requiring more efficient 
immunocomplex capturing, improved assay kinetics, and more efficient washing step 








The rapidly increasing number of publications and patents with LFAs indicates that the 
technology is becoming increasingly popular, although the basic concept has been in 
commercial production since the 1980s. The simplicity of the LFAs’ basic structure 
makes the assays relatively cost-effective to manufacture in automatized production 
lines. The development process for new products is relatively rapid and can be set in 
motion with relatively small initial costs, as the basic instrumentation required for 
small-scale prototype production include only a strip cutter and a line dispenser in 
addition to standard laboratory equipment.  
For a rapid diagnostic test to be suitable for use in the most resource poor conditions, 
the test kits must be stable in ambient temperatures for at least several months. The test 
procedure must be very simple to perform in order to minimize the risk of operator 
errors. The clinical sensitivity and specificity must be sufficient to provide helpful 
information for the medical practitioners. All these criteria must be fulfilled without 
sacrificing the affordability of the product. Although clinical diagnostics is the most 
dominant market segment of LFAs, the assay platform has become increasingly popular 
in applications for environmental monitoring, food safety and pharmaceutical industry.  
The main conclusions based on the original publications are presented below. 
I Up to 300-fold improvement of analytical sensitivity can be achieved by using 
Eu(III) nanoparticles as reporters in LFAs compared to colloidal gold reporters. 
Time-resolved detection for the elimination of non-reporter specific background 
signal can be efficiently reduced by using a pulsed excitation light source. 
II Blood anticoagulants used in venipuncture tubes have variable compatibility with 
LFAs. The blood samples collected in tubes containing K3EDTA as the 
anticoagulant resulted in significant interference by decreased reporter particle 
mobility. An LFA for measuring cardiac troponin in a serum was demonstrated 
with an analytical sensitivity of 41 ng/L.  
III A quantitative and user-friendly LFA for diluted whole blood samples can be 
developed using upconverting nanoparticles. Interfering sample matrix effects 
can be mitigated by diluting the sample fluid while still retaining sufficient 




agreement of results obtained from real patient was demonstrated by a linear 
regression analysis of the UNCP-LFA and ELISA (n: 36, R2: 0.86). 
IV A microparticle-based immunoassay platform suitable for point-of-care use was 
developed. The potential of achieving high analytical sensitivities was based on a 
less limited immunocomplex formation time than in LFAs, as the capture 
microparticles could be incubated with the reaction mixture as long as required. 
UCNP reporters can successfully be used in challenging measurement conditions 
where the plastic materials have significant autofluorescence properties.  
As the stand-alone capability of the LFAs to be used without any reader device makes 
the platform very convenient for diagnostic assays that are needed only occasionally, the 
need for higher analytical performance with LFAs indicates a growing trend of using 
reader devices with LFAs.151 Along with different reader instruments, different reporter 
technologies can be expected to gradually appear to the market. The UCNP technology, 
Eu(III) nanoparticles and Alexa Fluor reporters have already been included in 
commercial products, but a breakthrough by any particular reporter technology is yet 
to happen. For achieving optimal UCNP particles for LFAs, the balance of the size-
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